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Assessment of Apolipoprotein C- III as A predictor of Cardiovascular 
Diseases among Type 2 Diabetic Men in Gaza Strip 
Abstract 
Background: Diabetes mellitus is one of the most important risk factors for 
cardiovascular diseases. Apolipoprotein C-III (apo C-III) is a multifunctional protein 
that not only regulates the metabolism of triacylglycerols but also an important regulator 
of endothelial function. In the presence of hyperlipidema, apo C-III exerts 
proinflammatory effects on both monocytes and endothelial cells that are important for 
transendothelial migration of monocytes into the vessels‘ intima and development of 
atherosclerosis. 
Objectives: To investigate the prognostic value of plasma apo C-III concentrations for 
cardiovascular complication among  Type 2 Diabetes mellitus (T2DM) patients in Gaza 
strip.  
Subjects and methods: This study is a case-control study; a total of 89 male of  T2DM 
were evaluated and classified into two groups according to heart disease [52 of T2DM 
patients  without heart disease and 37 with heart disease] and equal number of normal 
subjects (n=89) were run in parallel with each group as a control. Apo C- and apoA1 
were measured using immunoturbidimetric methods. Glucose, creatine kinase (CPK), 
creatine kinase MB (CK-MB), aspartate aminotransferase (AST), Lactate 
aminotransferase (LDH), cholesterol, triacylglycerols (T.G) and, HDL-C were measured 
using colorimetric and kinetic method and low density lipoprotein (LDL-C) was 





Results: The concentration of apo C-, glucose, LDL, cholesterol, triacylglycerols, 
apoA1, LDH, AST, CPK and, CK-MB were significantly increased among T2DM 
patients (P<0.05). There was positive correlation between apo C- and plasma 
triacylglycerols in T2DM patients compared with control (r=0.755, p=<0.001 and 
r=0.426, p=0.001 respectively). Also, there were positive correlation between apo C- 
and glucose, cholesterols, AST and apoA1 among T2DM patients (r=0.238,p=0.012, 
r=0.340,p=0.001, r=0.237,p=0.013, r=0.242, p=0.011 respectively). There was 
statistically significant difference between apo C- (p<0.05) in the two cases groups of 
T2DM (with/without heart disease) and between the obese and non-obese T2DM 
patients. There was significant difference between apo C- and insulin treatment 
(p<0.05), while no significant difference was found between lipid-lowering drug and 
apo C-. 
Conclusion: High level of Apo C-III and low level of apoA1 concentration in plasma, 
independently of fasting triacylglycerols and other traditional risk factors, predicts 
cardiovascular mortality among T2DM patients. 
   
Keywords: apolipoprotein C-III, cardiovascular disease, type 2 Diabetes mellitus, 









يزضي انقهب و األوعيت انذيىيت انذيٍ نذيهى  عُذ Apolipoprotein C-III يستىيى  يتق
 في قطاع غزة انُىع انثاَيانسكزي يٍ يزض 
 
Abstract (Arabic) 
                                                                                                                    
 يهخص انذراست
 
ٕ٘  apo C-ٍشع اىسنشٛ ٕ٘ ٗاحذ ٍِ إٌٔ ػ٘اٍو اىخطش اىَسججخ ألٍشاع اىقيت ٗاألٗػٞخ اىذٍ٘ٝخ. يقذيت: 
زْظٌٞ اىذُٕ٘ اىضالصٞخ فٜ اىذً  ثو ٗ رْظٌٞ  ػَو اىخالٝب اىَجطْخ ىألٗػٞخ حٞش ٝقً٘ ث ثشٗرِٞ ٍزؼذد اى٘ظبئف
س رغٞشاد ػيٜ اىخالٝب اىَجطْخ ىألٗػٞخ ثئحذا apo C-ٝقً٘  صٝبدح غٞش ؽجٞؼٞخ فٜ اىذُٕ٘فٜ ٗج٘د  اىذٍ٘ٝخ.
اىذٍ٘ٝخ ٗ رْشٞؾ اىخالٝب اىَْبػٞخ ٗ ثبىزبىٜ ٝزسجت فٜ اىزٖبثبد فٜ االٗػٞخ اىذٍ٘ٝخ ٗ حذٗس أٍشاع رظيت 
 اىششاِٝٞ.
ػْذ ٍشػٜ اىسنشٛ ٍِ اىْ٘ع اىضبّٜ فٜ قطبع غضح.  apo C-: رقٌٞ اىقَٞخ اىحشجخ ىَسز٘ٛ انهذف يٍ انذراست 
ٍِ اىشجبه ٍقسَِٞ اىٜ  98ٍجَ٘ع ٍشػٜ اىسنشٛ ٍِ اىْ٘ع اىضبّٜ فٜ ٕزٓ اىذساسخ مبُ طزق: انًىاد و ان
ٍِ اٍشاع  ٍُشٝغ سنشٛ ٝؼبّ٘ 73ٍشٝغ سنشٛ فقؾ ٗ  25ٍجَ٘ػزِٞ حست اإلطبثخ ثأٍشاع اىقيت )
رٌ  ٍزط٘ع غٞش ٍظبثِٞ ثَشع اىسنشٛ أٗ أٛ أٍشاع أخشٙ مَجَ٘ػخ ػبثطخ . 98ثبإلػبفخ إىٚ  اىقيت(,
 فحض سنش ٗ اىذُٕ٘ ٗ اّضَٝبد اىقيت فٜ اىذً ,أٍب apo C-  ٗapoA1ىفحض اىؼنش اىَْبػٜ زخذاً رقْٞخ اس
  فزٌ قٞبسٖب ثبسزخذاً ٍ٘اد مَٞٞبئٞخ ىّ٘ٞخ ٗإّضَٝٞخ.
اىن٘ىٞسزشٗه ٗ اىن٘ىٞسزشٗه ٗ اىسنش ٗ  apo C-: أظٖشد اىذساسخ صٝبدح ٍيح٘ظخ فٜ ّسجخ رشمٞض  انُتــائــــــح
فٜ اىذً ػْذ ٍشػٜ اىسنشٛ  apoA1  ٗLDH  ٗAST  ٗCPK  ٗCK-MBاىسٞئ ٗ اىذُٕ٘ اىضالصٞخ ٗ 
(P<0.05) . اٝجبثٜ ثِٞ أظٖشد اىذساسخ ٗج٘د اسرجبؽapo C-  اىذُٕ٘ اىضالصٞخ ػْذ ٍشػٜ اىسنشٛ ٍقبسّخ ٗ
ٗ سنش اىذً ٗ  apo C-سرجبؽ إجبثٜ ثِٞ . مَب ٝ٘جذ ٗج٘د ا(r=0.755, p=<0.001)ثَجَ٘ػخ اىؼجؾ 
 (r=0.238,p=0.012, r=0.340,p=0.001 ػْذ ٍشػٜ اىسنشٛ AST  ٗapoA1اىن٘ىٞسزشٗه ٗ 





ٗ ثِٞ اىَشػٜ اىَظبثِٞ ثبىسَْخ ٗ اىغٞش ٍجَ٘ػزِٞ ٍشػٜ اىسنشٛ )ٍظبة اٗ غٞش ٍظبة ثأٍشاع اىقيت( 
ٗ ػالط اىسنشٛ ثبالّس٘ىِٞ ٗال ٝ٘جذ   apo C-راد دالىخ إحظبئٞخ ثِٞ   . مَب ٝ٘جذ فشٗق(p<0.05)ٍظبثِٞ
 .ػالقخ ثْٞٔ ٗ ثِٞ االدٗٝخ اىخبفؼخ ىيذُٕ٘
 فٜ اىذً ثِٞ ٍشػٜ اىسنشٛ apoA1ٗ إّخفبع  apo C-ّسزخيض ٍِ رىل أُ صٝبدح رشمٞض  : االســتـُــتاج
 ثئطبثخ ٍشػٜ اىسنشٛ ٍِ اىْ٘ع اىضبّٜ ثأٍشاع اىقيت ٗ االٗػٞخ اىذٍ٘ٝخ.َٝنِ اىزْجؤ  رٗ دالىٔ  ٍِ اىْ٘ع اىضبّٜ
, أٍشاع اىقيت, ٍشع اىسنشٛ ٍِ اىْ٘ع اىضبّٜ, اىذُٕ٘ اىغْٞخ apolipoprotein C- انكهًــاث انًفتــاحيــت :
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Cardiovascular diseases (CVDs) are a group of heart disorders , blood vessels and  
brain. CVDs are the number one cause of death and disability in the world. An 
estimated 17.3 million people died from CVD in 2008, representing 30% of all global 
deaths; an estimated 7.3 million were due to coronary heart disease (CHD) and 6.2 
million were due to stroke (Lee et al., 2003; World Health Organization, WHO,2008]. 
In occupied Palestinian territories, CHD is accounting 21% of all deaths and CVDs 
causes 11.0% of all deaths (Husseini et al., 2009). In 2009 evaluation, heart diseases 
were responsible for 17.1 % of all the total deaths in Gaza Strip and cerebrovascular 
diseases were responsible for 6% of the total deaths in Gaza strip (Ministry of 
Health,MOH, 2011). In 2011, heart diseases were reported in 22.4% of all population 
deaths in West Bank (MOH, 2012).  
 
Many of risk factors associated with CHD have been identified, such as unhealthy diet, 
physical inactivity, smoking, hypertension, raised blood glucose, dyslipidaemia, obesity, 
age, gender and genetic influence (WHO, 2008). The single most powerful predicator of 
CHD risk is abnormal lipid value (Hobbs, 2004) and hypertriacylglycerolemia is 
considered as an independent cardiovascular risk factor. Apolipoprotein C-III (apo C-
III) is an important determinant of the catabolic rate of triacylglycerol-rich lipoprotein 
(TRL) (Scheffer et al., 2008) and apo C-III is working as an inhibitor of the activity of 
apolipoprotein lipase (LPL) which metabolizes triacylglycerol in very low density 





lipoprotein (VLDL), chylomicron (CM) and facilitates their clearance from plasma. 
Moreover, apo C-III obstructs the clearance of the intermediate apolipoprotein (IDL) 
and low density lipoprotein (LDL) from plasma by interfering with their interaction 
with hepatic lipoprotein receptor. The high plasma concentration of Apo C-III  is 
associated with CHD and patients with Type 2 diabetes mellitus (T2DM) (Lee et al., 
2003). In addition, apo C-III stimulates monocyte adhesion to the endothelial bed by 
inducing expression of the vascular cell adhesion molecule-1(VCAM-1) in vascular 
cells. Therefore, the exposure of vascular endothelial cells to apo C-III result in the 
inhibition of insulin-stimulated endothelial nitric oxide synthase (eNOS) activity and 
nitric oxide (NO) production, thus suggesting a relationship between hyperlipidemia 
and endothelial cell dysfunction. Overall, these effects link apo C-III with the 
atherosclerotic process in a complex way beyond the obvious role in lipid metabolism 
(Olivieri et al., 2010). 
 
1.2 Diabetes mellitus as a risk factor for cardiovascular disease 
In the last few years, prevention of CVD risk factors have resulted in lowering CVD-
related mortality. However, many patients identify these factors but they do not have 
them adequately controlled (Christopher, 2007). T2DM is a heterogeneous group of 
metabolic diseases characterized by chronic hyperglycemia and disturbances in 
carbohydrate, lipid and protein metabolism resulting from defects in insulin secretion 
and/or insulin action. T2DM is a strong risk factor for CVD. T2DM has been diagnosed 
in 10 to 24% of patients with myocardial infarction (Tenerz et al., 2001). The 
mechanisms responsible for the increased cardiovascular risk factors in T2DM is not 





clear. Patients with T2DM have characteristic lipid abnormalities related to insulin 
resistance, such as hypertriacyglycerolemia, low HDL-cholesterol and lowered activity 
of LPL which metabolizes triacylglycerol in VLDL. Cardiovascular complications 
particularly CHD is the main cause of morbidity and mortality in T2DM. Some studies 
have shown that hypertriacyglycerolemia in diabetes is an independent cardiovascular 
risk factor (Gervaise et al., 2000). 
1.3 Objectives 
1.3.1 General objective 
To assess Apolipoprotein C-III in cardiovascular diseases among T2DM males in Gaza 
Strip  .  
1.3.2 Specific objectives 
 
1. To determine the level of serum apo C-III in patients and control. 
2. To measure serum lipid profile (cholesterol, T.G, HDL, LDL in patients and 
control. 
3. To measure serum level of CPK, CK-MB, AST,LDH), glucose, and apo A1 in 
patients and control. 
4. To correlate apo C-III  level with patient's lipid profile and cardiac enzymes 
compared with control. 
1.4 Significance 
Myocardial infarction carries significant morbidity and mortality burden among T2DM. 
Heart failure is also widely prevalent, with a reported prevalence of 17.1 % of all total 
deaths in Gaza strip and cerebrovascular diseases are responsible for 6% of the total 





deaths in Gaza strip (MOH, 2011). T2DM, obesity and dyslipidemia patients are among 
the main groups at high risk for the development of cardiovascular complications which 
could lead to CVD, atherosclerosis and myocardial infarction. Evaluation and 
management of patients at high risk of myocardial infarction can enhance early 
prognoses of future CVD complications and is of vital concern globally. Understanding 
the status of apo C-III and apo A1 among T2DM patients could provide clear picture of 
the main complications of this disease and enable us to advise policy makers to put new 
strategies to avoid these complications. No previous study investigated the role of apo 


















Diabetes is a chronic disease that occurs either when the pancreas does not produce 
enough insulin or when the body cannot effectively use the insulin it produces. 
Hyperglycaemia or raised blood glucose is a common effect of uncontrolled diabetes 
(World Health Organization,WHO, 2011). Several pathogenic processes are involved in 
the development of diabetes. These range from autoimmune destruction of the β-cells of 
the pancreas with consequent insulin deficiency to abnormalities that result in resistance 
to insulin action. The basis of the abnormalities in carbohydrate, fat, and protein 
metabolism in diabetes is deficient action of insulin on target tissues (American 
Diabetes Association) (ADA, 2004). The chronic hyperglycaemia of diabetes is 
associated with long-term dysfunction, damage and failure of various organs, especially 
eyes, kidneys, nerves, heart and blood vessels (ADA, 2000). 
2.2 Classification of  diabetes 
Diabetes can be classified into two major classes: type 1 diabetes mellitus (T1DM) and 
T2DM. In addition other minor classes include gestational diabetes mellitus (GDM), 
impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) (ADA, 2004). 
2.2.1 Type 1 diabetes mellitus 
T1DM is called juvenile-onset diabetes or insulin dependent diabetes mellitus (IDDM). 
It's associated with absolute deficiency of insulin secretion. The disease process become 
more severe  in which the immune system improperly recognizes the insulin-producing 




β-cell in pancreas as foreign body and destroyed them. This form develops most 
frequently in children and adolescents (Jenni et al., 2004). In this  type of diabetes, 
patients cannot survive without insulin treatment (Ahmed et al., 2010). In T1DM the 
rate of β-cell destruction is quite variable being rapid in some individuals (mainly 
infants and children) and slow in other (mainly adult). Some patients particularly 
children and adolescent may present with ketoacidosis as the first manifestation of 
disease. Other have hyperglycemia that can rapidly change to sever hyperglycemia 
and/or ketoacidosis in the presence of infection or stress (ADA, 2004). 
2.2.2 Type 2 diabetes mellitus 
T2DM is called non-insulin dependent diabetes mellitus (NIDDM) or adult onset 
diabetes. T2DM involves insulin resistance and relative insulin deficiency rather than an 
absolute insulin deficiency as seen in T1DM. Insulin resistance is thought to precede 
insulin deficiency in most patients, and autoimmune destruction of β-cells does not 
occur, although β-cell mass may be reduced. Because the insulin deficiency is relative 
rather than absolute, diabetic ketoacidosis occurs less frequently than in type 1 diabetes 
(Michael, 2007). In this type of diabetes, patients are controlled by diet, hypoglycaemic 
agent and/or exogenous insulin (Ahmed et al., 2010). Most T2DM patients are obese, 
and obesity itself causes some degree of insulin resistance. Patients who are not obese 
may have an increased percentage of body fat distribution in the abdominal region 
(Jennifer.M, 1998). Exercise and weight loss lead to improvements in the disease state 
and even clinical remission in some individuals (Michael, 2007). This form of diabetes 
frequently goes undiagnosed for many years because the hyperglycemia develops 
gradually and at earlier stage is often not sever enough for patient to notice any of 
symptoms of diabetes, whereas T2DM patients may have insulin levels normal or 




elevated. Thus insulin secretion is defective and insufficient to compensate for insulin 
resistance (Jennifer, 1998). 
2.2.3 Gestational diabetes mellitus 
Gestational diabetes mellitus (GDM) is a form of hyperglycemia results from an insulin 
supply that is inadequate to meet tissue demands for normal blood glucose regulation 
(Thomas et al., 2005). Insulin resistance usually begins in the second trimester and 
progresses throughout the remainder of the pregnancy. Placental secretion of hormones, 
such as progesterone, cortisol, placental lactogen, prolactin, and growth hormone, is a 
major contributor to the insulin-resistant state seen in pregnancy (Tracy et al., 2005). 
2.3  Prevalence of diabetes 
  
The world prevalence of diabetes among adults (aged 20-79 years) was approximately  
6.4% affecting 285 million adults in 2010 (Karthik et al., 2012). In 2011, the incidence 
rate of new reported cases with diabetes 154.4 per 100,000 of population, 94.6% of 
these cases T2DM in West Bank (MOH, 2012). In Gaza strip, Diabetes representing 
24.2/10,000 of population in 2009 (MOH, 2011).  
2.4 Diabetes mellitus symptoms 
Symptoms of marked hyperglycemia include polyuria, polydipsia, weight loss, 
sometimes with polyphagia, and blurred vision. Impairment of growth and susceptibility 
to certain infections may also accompany chronic hyperglycemia. Acute, life-
threatening consequences of uncontrolled diabetes are hyperglycemia with ketoacidosis 
or the non-ketotic hyperosmolar syndrome (ADA, 2004). 
 
  





Apolipoproteins are polypeptides found in various types of lipoproteins, apolipoproteins 
act as a transport of chylomicron(CM), triacylglycerol, Cholesterol, fatty acids, 
cofactors or activators of enzyme like lecithin-cholesterol acyltrasferase (LCAT) and 
LPL (Irshad and Dubey, 2005). Plasma apolipoprotein can be classified into two 
classes: nonexchangeable apolipoproteins (apoB-100 and apoB-48) and exchangeable 
apolipoproteins (apoA-І, apoA-ІІ, apoA-IV, apoC-I, apoC-II, apoC-III, and apoE) (Jere 
et al., 2001) (Table 2.1). 
Table 2.1 Classification and properties of major human plasma apolipoproteins 







Apo A- 11 Cofactor LCAT CM, HDL 
Apo A- 1 Not known HDL 
Apo A- IV 
11 Activated of LCAT CM, HDL 
2 
Secretion of T.G from liver, 
binding protein to LDL receptor 
VLDL, IDL, LDL 
Apo B-48 2 Secretion of T.G from intestine CM 
Apo B-100 2 Cholesterol transport from liver LDL 
Apo C- 19 Activation of LCAT CM, VLDL, HDL 
Apo C- 19 Cofactor of LPL CM, VLDL, HDL 
Apo C- 11 Inhibition of apo C- and LPL CM, VLDL, HDL 
Apo D 3 unknown HDL 
Apo E 19 
Facilitation of uptake of 
chylomicron remnant and LDL 
CM, VLDL, HDL 
Apo (a) 6 unknown Lp (a) 
Chylomicron (CM), high density lipoprotein (HDL), very low density lipoprotein (VLDL), 
intermediate density lipoprotein (IDL), low density lipoprotein (LDL), lipoprotein a (Lp a), 
 
  




2.5.1 Biochemistry of apolipoprotein C- 
Apolipoprotein C-III (apo C-III) is a component of triacylglycerol-rich lipoprotein 
(TRLs), LDL, CM and HDL particles. Apo C- is the most abundant apolipoprotein in 
VLDL particle , account for 40-60% of VLDL,  2% of HDL and 10%-20% of LDL 
protein (Mendivil et al., 2011). Various nomenclatures have been used to describe 
lipoproteins containing apo C-III. (Alaupovic et al., 1992) First defined the term LpB:C 
to describe the concentration of apoB-containing lipoproteins enriched with apo C-III. 
The development of methods to measure apo C-III concentrations led to additional 
terminologies. For example, apo C-III-LpB and apoC-III-non-LpB describes the 
concentration of apo C-III associated with apoB-containing lipoproteins and non-apoB-
containing lipoproteins respectively (Luc et al., 1996). It is correlated closely with 
concentrations of serum total and VLDL triacylglycerol (Hiukka et al., 2005). Apo C-III 
is small exchangeable apolipoprotein that synthesis by liver and to a lesser extent by 
intestines as a 99 amino acids (Sundaram et al., 2010), after remove 20 amino acids in 
the endoplasmic reticulum, a mature apo C-ІІІ protein consists 79 amino acids long 
glycoprotein with molecular mass of 8.8 kilodaltons (KDa) (Chhabra et al., 2004; 
Kawakami  and Yoshida, 2008). Apo C-ІІІ contains two helices that are amphipathic 
(having polar and nonpolar groups), thereby allowing interaction with both lipids and 
water (Gangabadage.C et al., 2008). Apo C-ІІІ is present as a non-glycosylated isofom 
(apoC-ІІІ0) or as a glycosylated isoform with one or two sialic acid (apoC-ІІІ1 and 
apoC-ІІІ2 respectively). All three isoforms have the same half-life in plasma, suggesting 
similar synthesis and catabolic mechanisms and possibly similar physiological function 
(Esther.O et al., 2008). 
  




2.5.2 Apo C-ІІІ gene regulation 
The apolipoprotein (apo) genes apoA-І, apo C-ІІІ and apoA-IV are closely linked and 
tandemly organized within a 15-kb (kilobases) DNA segment of the long arm of human 

















Figure 2.1 Schematic representation of the apo C-III gene. 
peroxisome-proliferator-activated receptor alpha (PPARα) and insulin are agonists inhibit 
the expression of apo C-III, whereas inflammatory signalling (e.g. nuclear factor κB (NF-κB) 
induces the expression of apo C-III, insulin response element (IRE) (Esther et al; 2008).   
 
Apo C-ІІІ gene activity is tightly regulated by hormones such as insulin or thyroid 
hormones, cytokines as interleukin-1 (IL-1) or tumor necrosis factor α (TNF-α) as well 
as hypolipidemic drugs such as fibrates or β-blocked fatty acids. By contrast , it's 
expression is increased by retinoids (Raspe et al., 2002). Under normal condition, 
peroxisome-proliferator-activated receptor (PPARγ and PPARα), Rev-erbα, Farnesoid 
X receptor and insulin are inhibited apoC-ІІІ gene expression whereas glucose 
stimulates apo C-ІІІ gene expression. Plasma free fatty acids (FFA) stimulate apo C-ІІІ 
secretion but it not known whether this occurs at transcription or post translational level 
(Ginsberg and Brown, 2011). ApoCs  are involved in the regulation of fat transport in 
plasma and maintaining energy flux (Esther et al., 2008).  




In state of insulin resistance, any inhibitory role of insulin on apo C-ІІІ expression may 
be lost, whereas higher glucose levels as in patients T2DM would further stimulate apo 
C-ІІІ expression. Increased plasma FFA delivery to the liver would exacerbate this 
problem. The results of unregulated apo C-III synthesis and secretion would be 
defective lipoprotein lipase–mediated lipolysis of TRLs and reduced remnant 
lipoprotein clearance (Ginsberg and Brown, 2011) (Figure 2.2). Thus, apo C-III causes 
accumulation in plasma of atherogenic remnant lipoproteins and LDL rich in apo C-III, 
T.G, and cholesterol, which are prominent in diabetic and atherogenic dyslipidaemia 
(Cohn et al., 2004). Plasma levels of apo C-III containing VLDL and LDL predict risk 




Figure 2.2 Regulation apo C-ІІІ.   A Under normal conditions, apoCIII gene expression and 
synthesis are regulated by several factors. B In states of insulin resistance, any inhibitory role of 
insulin on apo CIII expression may be lost, FFA free fatty acid, FXR farnesoid X receptor, 
VLDL very low density lipoprotein, apoB apolipoprotein B, LPL lipoprotein lipases (Ginsberg 
and Brown,2011).  




2.6 Effects of apolipoprotein C- on triacylglycerol and lipoprotein 
metabolism 
The mechanisms through which apo C-III regulates the catabolism of TRL are complex 
and involve both lipolysis and cellular uptake of these particles (Jong et al., 2001). 
When TRLs, such as chylomicrons and very low density lipoproteins (VLDL), enter the 
circulation, they acquire apoCs and apoEs from circulating high density lipoproteins 
(HDL) (Mahley et al., 1984). These exchangeable apolipoproteins are usually present in 
multiple copies on each triacylglycerol-rich particle (Luc et al., 1996). Apo C-ІІІ was 
found in the broad distribution of particles the size of VLDL, on particles slightly larger 
than LDL, and on particles slightly larger than HDL. It has been reported that in the 
fasting state, apoCs are mainly associated with HDL (Gibson et al., 1985). During the 
hydrolysis of VLDL triacylglycerols by LPL, apo C-III redistributes from VLDL to 
HDL, and is subsequently transferred back to newly synthesized TRL particles (Esther 
et al., 2008) (Figure 2.3). LPL is abundantly expressed only on the vascular surface 
endothelial that line the capillary beds of cardiac, skeletal muscle and adipose tissues. 
This enzyme hydrolyses triacylglycerols in the cores of CM and VLDL to form 
monoacylglycerol and fatty acids. Fatty acids that are taken up by muscle cells are 
consumed by oxidative metabolism as a direct source of energy. Within adipose tissue, 
fatty acids are reesterified and stored as triacylglycerols droplets (Mead et al., 2002). 
 
Before encountering LPL, triglyceride-rich CM and VLDL particles must first acquire 
apo C-II which is required for LPL activity. Apo C-II molecules are acquired by CM 
and VLDL by exchange from HDL particles (Fielding and Fielding, 2002). Lipolysis of 
apoB-containing particles continues until about 80% of the initial triacylglycerol 




content has been removed from CM and about 50% from VLDL. At this point, apo C-II 
is transferred to HDL, and HDL-associated apoE is acquired. The resulting CM and 
VLDL particles that contain apoE but lack apo C-II are referred to as ‗remnants‘  
(Mahley and Ji, 1999). ApoE facilitates hepatic removal of the resulting remnant 
particles (Windler et al., 1980). ApoE is thought to play a role in the clearance of 
lipoproteins including CM and VLDL remnants, IDL, LDL, and HDL by receptor 
pathways. In the fasting state, apoCs are mainly associated with HDL, in the fed state, 
they preferentially redistribute to the surface of CM and VLDL particles (Figure 2.3) 
(Jong et al., 1999). 
 
Figure 2.3 Pictorial representation of the free exchange of apo C-III between apoB-
containing lipoproteins and HDLs in the circulation (Esther et al; 2008). 
 
Apo C-III is a major regulator of lipolysis, as it noncompetitively inhibits endothelial-
bound lipoprotein lipase, the enzyme that hydrolyzes T.G in TRLs, which generates 
smaller triacylglycerol-depleted remnant lipoproteins (Bobik, 2008). Apo C-ІІІ inhibits 
lipolysis and displacement of apolipoproteins from lipoprotein particles. Displacement 
of apo C-ІІ from lipoprotein would reduce apo C-ІІ mediated activation of LPL, 
resulting in a diminished catabolic rate of VLDL and CM and induction of 
hypertriacylglycerolemia. Similar, increased level of apo C-ІІІ would displace apoE, a 




crucial ligand for remnant removal which would result in decreased remnant clearance 
(Dijk et al., 2004). 
At higher concentrations also inhibits hepatic lipase (HL) activity (Jong et al., 2001), an 
enzyme with triacylglycerol lipase and phospholipase A1 activity, that is synthesized in 
the liver (Esther et al., 2008)(Figure 2.4). 
 
Figure 2.4 Apo C-III regulates lipoprotein metabolism by multiple mechanisms. 
ABCA1, ATP-binding cassette A1; CE, cholesterol ester; FC, free cholesterol; SR-B1, 
scavenger receptor B-1(Esther et al; 2008). 
 
 
Furthermore, it reduces the binding of VLDL by glycosaminoglycan and also hampers 
apoE-mediated remnant removal by displacing apoE from the VLDL particles in vivo 
and thus impedes triacylglycerols clearance, leading to an increase in the circulation 
time of the triacylglycerol-rich particles (Aalto et al., 1996). Apo C-III can abolish 
apoB- and apoE mediated binding of lipoproteins to LDLR (LDL receptor) (Clavey et 
al., 1995) (Figure 2.4). The binding of chylomicrons and VLDL particles to the LSR 
(lipolysis-stimulated receptor) is also significantly inhibited by apo C-III (Mann et al., 




1997). Apo C-III and apoE have both been shown to interact and inhibited LDL 
receptor-related protein (LRP), scavenger receptor B-1 (SR-BI) and ATP-binding 
cassette A1 (ABCA1) (Cohn et al., 2003). 
 
LCAT (lecithin cholesterol acyltransferase) and CETP (cholesteryl ester transfer 
protein) are involved in TRL and HDL metabolism. The regulatory effect of apo C-III 
on LCAT activity, an enzyme that catalyses the maturation of nascent to mature HDL, 
remains conflicting (Nishida et al., 1986). It is thought that apo C-III may regulate 
LCAT activity indirectly through apolipoproteins that activate LCAT, although further 
studies are required. Little has been published concerning the effects of apo C-III on 
CETP, a glycoprotein that facilitates the exchange of neutral lipids between TRL and 
HDL particles. A preliminary finding from a study using recombinant HDL particles 
suggests that apo C-III may stimulate CETP activity (Esther et al., 2008).  
2.7 Pathogenisty of apo C-ІІІ on T2DM 
Patients with (T2DM) have 2 to 3 times higher the risk of coronary heart disease (CHD) 
than non-diabetic's (Stamler et al., 1993). Plasma cholesterol, LDL cholesterol, and 
HDL cholesterol (HDL-C) are strong risk factors for CHD in T2DM. Diabetic patients 
have higher plasma triglyceride concentrations than non-diabetic patients (Lee et al., 
2003). Dyslipoproteinemia involve  elevated VLDL, lower HDL cholesterol, and altered 
distributions of particles in all lipoprotein classes (Brunzell et al., 2008). Insulin 
resistance stimulates hepatocyte apo C-III production, plasma apo C-III level is elevated 
in patients with T2DM, metabolic syndrome and is associated with body mass index 
(Ginsberg and Brown, 2011). Elevated plasma apo C-III levels have potential to 
decrease TRL hydrolysis and delayed clearance remnant of TRL particles, resulting 




accumulation of VLDL-TG and CM in plasma and development of 
hypertriacylglycerolemia (Altomonte et al., 2004). Defective inhibition of LPL by apo 
C-ІІІ might raise levels of circulation non-esterified fatty acids (NEFAs) and thus affect 
insulin sensitivity and beta cell function (Hoek et al., 2011). Apo C-III was found to 
directly affect insulin secretion by interfering with voltage-gated calcium channels in 
pancreatic-cells (Gangabadage et al., 2008). Also patients with (T2DM) increased levels 
of circulating  Apo C-III, and it has been linked to enhanced  β-cell apoptosis (Sol et al., 
2009). Hypertriacylglycerolemia is major independent risk factor for CHD and 
atherosclerosis, it is also a prominent feature of dyslipidemia in T2DM. Chylomicrons 
and their remnants, as well as VLDL remnant can penetrate into and be trapped inside 
the artery wall, where they can be taken up by macrophages and smooth muscle cells, 
which considered  pro-athergenic in artery wall (Ginsberg, 2002). Increase production 
of VLDL-TG lead to increase apoB-lipoprotein acceptors for cholesterol transfer by 
cholesterol esters transfer protein (CETP). As a result HDL become depleted of 
cholesterol and LDL levels increase (Rader, 2007) (Figure 2.5). 
 
The content of apo C-III in LDL is an in independent risk factor for coronary events in 
diabetic patients (Lee et al., 2003). Apo C-ІІІ reduce LDL receptor activity , causes long 
residence time, high concentrations, and prolonged exposure of vascular wall cells to 
circulating LDLs (Zheng et al., 2007) , and has also increased the binding of LDL to 
artery wall proteoglycans (Hiukka et al., 2009), and become more susceptible to 
oxidation (Dokken, 2008). Oxidized LDL is pro-atherogenic because it is  acquire new 
properties that are recognized by the immune system as ―foreign.‖ Thus, oxidized LDL 
produces several abnormal biological responses, such as attracting leukocytes to the 




intima of the vessel, improving the ability of the leukocytes to ingest lipids and 
differentiate into foam cells, and stimulating the proliferation of leukocytes, endothelial 
cells, and smooth muscle cells (Chan, 1998), all of which are steps in the formation of 
atherosclerotic plaque (Dokken, 2008). 
 
Figure 2.5 Atherogenic mechanisms of apo C-III (Bobik, 2008) 
 
Accumulation of foam cells results of plaques and rupture of these plaques can lead to 
an infarct, damaging surrounding tissue (Lusis, 2000). All of which are steps in the 
formation of atherosclerotic plaque (Dokken, 2008). Finally apo C-III also stimulates 
adipocytes to produce cytokines and suppresses their production of adiponectin 
(Kawakami et al., 2010). These actions, converting adipocytes into a proinflammatory 
phenotype, may act indirectly to promote the development of atherosclerosis (Sacks et 
al., 2011). 




2.8 The effect of apo C- III on endothelial cells and monocytes 
Endothelial dysfunction plays an important role in the pathogenesis and clinical 
expression of atherosclerosis (Creager et al., 2003). It is characterized by the reduced 
bioavailability of nitric oxide (NO) which produced by endothelial nitric synthase 
(eNOS), not only causes vasodilatation but also prevents leukocyte adhesion and 
maintains the endothelium in a quiescent, anti-inflammatory state. Insulin promote 
bioavailability NO production by stimulate eNOS (Balasubramaniam et al., 2012). Apo 
C-ІІІ in VLDL inhibited insulin activation of eNOS pathway and production of NO in 
vascular endothelial cells in T2DM (Kawakami et al., 2008). High level apo C-III or a 
component of VLDL or LDL induce activation of protein kinase C (PKCβ) as well as 
(PKCα) and increase expression of vascular cell adhesion molecule-1 (VCAM-1) in 
non-activated endothelial cells (Kawakami et al., 2006), thus recruiting the adhesion of 
monocytes (Kawakami et al., 2010) , also PKCβ inhibits signal insulin in the same cells, 
result insulin resistance (Kawakami et al., 2008).  
 
The induction of adhesion molecules in vascular endothelial cells (ECs) and the 
subsequent recruitment of circulating monocytes are proinflammatory events that 
promote atherogenesis and plaque instability (Ross, 1999). 
2.9 Previous studies 
                              
Clinical and genetic studies show a strong correlation between apo C-III  and 
hypertriacylglycerolemia, and demonstrated the important of apo C-III as predictor 
cardiovascular disease outcome.  




2.9.1 Clinical studies 
Both CLAS (Cholesterol-Lowering Atherosclerosis Study) and MARS (Monitored 
Atherosclerosis Regression Study) demonstrated that plasma apo C-III predicted 
progression of angiographic coronary artery disease. (Blankenhorn et al., 1990). CLAS 
also reported that a decrease in apo C-III-non-LpB was a significant independent 
predictor or increased progression of coronary lesions. In MARS, apoC-III-LpB 
predicted the risk of progression, independent of LDL-cholesterol concentrations. The 
ECTIM (Etude Cas-Temoin de l‘Infarctus du Myocarde) study reported that subjects 
post myocardial infarction had increased apoC-III-LpB levels compared with healthy 
control subjects (Marcous et al., 2001). Although most apo C-III is carried on HDL, 
there is a close correlation between plasma levels of apo C-III and of apoC-III- and 
apoB-containing lipoprotein particles (LpB:C-III), and plasma triacylglycerols levels; 
this correlation has been documented both in normal individuals and, extensively, in 
patients with renal failure. Similar observations have been made in T2DM (Alaupovic et 
al., 1992). 
 
In addition, complete apo C-III deficiency has been reported in several families, with 
one family showing an increased fractional catabolic rate of VLDL and an unusually 
efficient conversion of VLDL to IDL and LDL (Jong et al., 2001). 
Petersen et al., (2010) reported the APOC3 variants C-482T and T-455C lead to 
increased plasma concentrations of apo C-, which in turn inhibit lipoprotein lipase 
and triglyceride clearance, thus conferring a predisposition to both fasting and 
postprandial hypertriacylglyceridemia due to an increase in chylomicron-remnant 
particles. Increased concentrations of circulating chylomicron-remnant particles are then 




preferentially taken up by the liver by means of a receptor-mediated process, resulting 
in non-alcoholic fatty liver disease and hepatic insulin resistance. 
 
2.9.2 Genetically modified mice 
A series of investigation in transgenic mice has confirmed the importance of apo C-ІІІ 
and help to resolve questions regarding it mechanism of action. Apo C-III-knockout 
mice had normal intestinal lipid absorption and hepatic VLDL triacylglycerols 
secretion, but a rapid clearance of VLDL triacylglycerols and VLDL cholesteryl esters 
from plasma that may explain the observed hypolipidaemia (Gerritsen et al., 2005). 
Overexpression of apo C-III in transgenic mice leads to severely increased plasma 
triglyceride levels due to accumulation of very low density lipoprotein-like lipoprotein 
remnants with increased apo C-III and decreased apoE content compared with controls  
(Clavey et al., 1995), resulting mainly from inhibition of LPL mediated triacylglycerol 
lipolysis (Ginsberg, 2002). In human subjects, increased levels of apo C-III often 
correlated to increased levels of triacylglycerols in blood and in turn to insulin 
resistance, cardiovascular disease, and T2DM (Gangabadage et al., 2008). 
2.10 Apo C-ІІІ predicts cardiovascular disease in T2DM  
Cardiovascular disease is a major cause of morbidity and mortality in T2DM. Most of 
the patients die from cardiovascular complications, particularly from ischaemic heart 
disease (Koskinen et al., 1992). The mechanisms responsible for the increased 
cardiovascular risk in T2DM patients are not fully understood. Diabetes is associated 
with many well-established cardiovascular risk factors. Patients with T2DM have 
characteristic lipid abnormalities related to insulin resistance, i. e. 
hypertriacylglycerolemia and low HDL-cholesterol (Ginsberg, 1996). In cross-sectional 




study ,demonstrated independent association between triacylglycerol, apo C-III, Lp 
B:C3 and macroangiopathy, especially coronary heart disease in T2DM patients 
(Gervaise et al., 2000). 
 
The presence of apo C-III on LDL is also associated with compositional changes that 
favor LDL adhesion to the subendothelial extracellular matrix (Hiukka et al., 2009). 
Thus, apo C-III may trap its associated lipoproteins in the arterial wall and bring in 
blood monocytes, crucial steps in the initiation and progression of atherosclerosis. Apo 
C-III concentrations in VLDL and LDL are positively associated with the progression 
of atherosclerosis or risk of coronary heart disease (CHD), and it was reported that LDL 
with apo C-III is associated with recurrent cardiovascular disease among patients with a 
prior myocardial infarction and T2DM (Mendivil et al., 2011). Lee et al., (2003) also 
reported that patients with T2DM have the plasma concentration of  apo C-III in LDL 
and VLDL particle strongly predicted recurrent coronary events in diabetic patients who 
had myocardial infarction. Apo C-III can stimulate several processes involved in 
atherogenesis and vascular inflammation. 
 
 Apo C-ІІІ stimulates blood-born monocyte and endothelial cell to produce cytokines as 
TNF-α and adhesion molecules and activates insulin-resistance pathway in endothelial 
causing endothelial dysfunction. Interaction of apo C-III with TRL at the cell surface act 
as an initiating events in this function (Sacks et al., 2011). Together, these factors are 
strong indications that apo C- ІІІ promote atherosclerosis not only by impairing 
catabolism of TRL but also stimulating vascular retention of lipoprotein and endothelial 
activation (Scheffer et al., 2008).  
 





Atherosclerosis is the general term for the thickening and hardening of the wall of 
medium size and large arteries. This results in the loss of elasticity, due to subsequent 
deposition of fat, cholesterol, cellular waste products, calcium and fibrin in the inner 
coating of an artery, and proliferation of connective tissue. Eventually, the vessel can 
become totally occluded. The plaques building up in these arteries can lead to 
myocardial infarction (heart attack), stroke, CHD, abdominal aortic aneurysm, kidney 
disease, mesenteric artery ischemia, peripheral artery disease, renal artery stenosis, 
hypertension and thoracic aortic aneurysm and other clinical syndromes, depending on 
the anatomical locations of the lesions that narrow the arteries (Figure 2.6) 
 
Figure 2.6 Atherosclerosis. Artery narrowed by plaque build-up, leading to heart attack or 
stroke. Health Care Tips. Last modified 1 May 2010.http://healthcaretips-fact-
guide.blogspot.com/2010/05/atherosclerosis-causes-risk-factors.html (Accessed 25 Nov. 
2011). 
 
Circulating LDL cholesterol moves into the subendothelial space. Trapped LDL is 
subjected to oxidative modification by vascular cells such as smooth muscle cells, 
endothelial cells, and macrophages. Macrophages uptake modified LDL (ox-LDL) by 




scavenger receptors. In LDL overload, macrophages transform themselves into foam 
cells which become necrotic due to the accumulation of oxidized LDL. Oxidized LDL 
also results in endothelial dysfunction and injury. Local inflammation increases the entry of 




Figure 2.7 A schematic illustration of foam cell formation in atherosclerosis (Adapted from 
Diaz et al., N. Engl. J. Med., 1997. [68]). 
 
2.12 Therapeutic regulation of Apo C- 
2.12.1 Statins 
Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase, a key enzyme in 
cholesterol synthesis. Inhibiting this enzyme results both in a decreased hepatic 
cholesterol secretion as well as in an up-regulation of the LDL receptor to maintain 
cellular cholesterol homeostasis (Grundy, 1998). The drugs would not alter plasma 




triacylglycerol levels, However, more recent studies have shown that statins can have 
significant triacylglycerol lowering actions in patients with hypertriacylglycerolemia if 
the drugs are given in high dose or new, more potent agents are employed (Packard, 
2003). statins lower the plasma concentration and cellular mRNA levels of apo C-III 
(Table 2.2 ). Although the precise mechanism for the effects of statins on apo C-III is 
not fully understood, it may relate to the activation of hepatic PPARα protein and, 
hence, a reduction in the expression and secretion of apo C-III. Furthermore, statins 
improve insulin action in subjects with hypertriacylglycerolemia, an insulin-dependent 
down-regulation of apo C-III gene transcription via the insulin response element (IRE) 
in the apo C-III promoter (Ooi et al., 2008). Insulin sensitizing therapy with the PPARα 
agonist pioglitazone in patients with T2DM reduced apo C- II production, plasma apo 
C-III concentration, and lowered plasma triacylglycerols (Pavlic et al., 2008). 
2.12.2 Peroxisome-proliferator-activated receptor  agonists 
PPARs are nuclear transcription factors that regulate the expression of genes involved 
in lipid and lipoprotein metabolism. There are three PPAR isoforms (PPARα, PPARγ 
and PPARδ), increased expression of LPL, apoA-I and apoA-II and reduced expression 
of apo C-. PPARα agonists, also known as fibrates, regulate lipid metabolism and 
may diminish CVD events. Fibrates have been shown to be highly successful agents in 
lowering the plasma concentration of small, dense LDL, A 36% reduction in plasma apo 
C-III levels was reported with fenofibrate treatment in the metabolic syndrome. PPARγ 
agonists, such as pioglitazone and rosiglitazone, improve insulin sensitivity in muscle, 
liver and fat, and are efficacious therapies in treating diabetic dyslipidaemia ( Packard, 
2003; Ooi et al., 2008) ( Table 2.2 ). 




2.12.3 FXR (farnesoid X receptor) agonists 
Previous studies have reported that FXR agonists decrease plasma triacylglycerol and 
apo C-III concentrations. The mechanism is unclear, but may relate to the 
downregulation of apo C-III mRNA and protein expression (Claudel et al., 2003).  
2.12.4 Ezetimibe 
Ezetimibe is a cholesterol absorption inhibitor that blocks the intestinal absorption of 
both biliary and dietary cholesterol (Bays et al., 2008). Nakou et al.,(2010) showed that 
ezetimibe administration, alone or combined with orlistat, decreases plasma apoC-II and 
apo C-III in obese patients with hypercholesterolemia. 
2.12.5 Fish oils 
n−3 Polyunsaturated fatty acids contained in fish oils may exert triacylglycerol- and apo 
C-III-lowering effects. The mechanism underlying the apo C-III-lowering effect of fish 
oils is unclear, but may relate to the activation of PPARα (Swahn et al., 1998; Ooi et al., 
2008). 
2.12.6 Niacin 
Nicotinic acid (or niacin) confers beneficial effects on all major plasma lipid and 
lipoprotein fractions, particularly by increasing HDL-cholesterol concentrations and 
decreasing both LDL-cholesterol and triacylglycerol concentrations. In addition, niacin 
has been shown to reduce VLDL-apo C-III concentrations in subjects with 
hyperlipidaemia. However, the exact regulatory effect of niacin on apo C-III 
metabolism is unclear and warrants further study (Ooi et al., 2008). 




2.12.7 Lifestyle modifications 
Weight loss has been associated with a reduction in plasma apo C-III concentrations in 
postmenopausal women (Fernandez et al., 2004). The underlying mechanism of action 
of weight loss on apo C-III metabolism requires further study, but it is likely to be 
associated with improved insulin sensitivity and reduced hepatic secretion of apo C-III. 
Consumption of diets high in MUFAs (monounsaturated fatty acids) resulted in a 
significant reduction in plasma apo C-III and fasting triacylglycerol levels (Desroche et 
al., 2008).By contrast, a low-fat and high carbohydrate diet was associated with 
increased apo C-III and triacylglycerol concentrations (Shin et al., 2007). 
 
Table 2.2 Mean percentage changes in total plasma apo C-III and lipid and lipoprotein 
concentrations in subjects with dyslipidaemia following lipid-regulating interventions ↑, 
increase; ↓, decrease (Esther et al., 2008) 
 
Intervention Apo C- Triacylglycerols LDL-C HDL-C 
Statin    27%  7-30%  18-55%  5-15% 
Fibrates   36%  20-50%  5-20%  10-20% 
Ezetimibe   21%  6-11%  12-14%  1-5% 
Niacin   31%  20-50%  5-25  15-35% 
Fish oil  0-5%  25-44%  5-25  0-8% 
Weight loss   9%  5-15%  5-18  0-9% 








































Materials and Methods 
3.1 Study design 
The design of the study is a case control study. 
 
3.2 Study population 
The target population of this study is T2DM male patients aged > 40 years, classified 
into three groups according to the year of diagnosis: 
1) T2DM patients < 5yrs.  
2) T2DM patient's ≥ 5yrs. 
3) T2DM patients with heart disease. 
The control group consists of age matched people who don't have diabetes mellitus and 
heart diseases. 
 
3.3 Sample size 
According to previous studies, the prevalence of T2DM is about 9%. The sample size of 
the study is calculated by using the formula of WHO/WFP/UNHCR/IFRC with 95% 
confidence interval, 3% margin of error and 9% prevalence of diabetes and based on 
studies that carried out in Palestine. Accordingly a total of 89 samples of diabetic males 
were collected distributed as 52 T2DM patients without heart disease, and 37 T2DM 
with heart disease; another 89 samples of age matched controls were collected. 
 
3.4 The study setting 
T2DM patient's samples were collected from a wide region of Gaza Strip which 
included primary health care, Union Palestinian Medical Relief Commits "UPMRC" 




(which cover all Gaza regions), EL-Shifa hospital, which covers the Northern zone of 
Gaza Strip and Gaza city, and Naser hospital which covers the Southern and middle 
zone of Gaza Strip. An age matched normal control samples were collected according to 
age and region. 
 
3.5 Inclusion criteria 
All T2DM patients with or without heart disease regardless treatment protocol were 
included. 
 
3.6 Exclusion criteria 
1) Pregnant women. 
2) Patients with liver diseases. 
3) Type 1 Diabetes mellitus patients. 
 
3.7 Ethical considerations 
All necessary approvals have been obtained from the Islamic university of Gaza Dean 
of research affairs (Annex1), approval from the directorate general of human resources 
development obtained on the (Annex 2), approval from Helsinki committee obtained on 
the (Annex 3).  Helsinki committee is an authorized professional body for giving 
permission to researchers to conduct their studies with ethical concern in the area. The 
participants were given a full explanation about the purpose of the study and assurance 
about the confidentiality of the information and an approval from the study participants 
were considered. 
  




3.8 Data collection 
Data was collected by the researcher herself. However, the following are the tools that 
were used in the study by the researcher. 
i. Face to Face questionnaire. 
ii. Blood analysis. 
 
3.8.1 Questionnaire 
A meeting interview was used to answer a questionnaire which was designated for 
matching the study need. All interviews were conducted face to face by the researcher 
herself. The questionnaire (Arabic version 1,annex 4 and English version Annex 5) 
included questions about: Personal, demographic and socio-economic data such as, age, 
address, marital status, educational level, physical activity, smoking, family history of 
diabetes), clinical data (duration of DM), and the most important complications of 
diabetes (retinopathy, cardiovascular disease (CVD), hypertension (HTN) and 
neuropathy and others were covered in the first part. The second part included the 
anthropometric measurements (height, weight). During the study the researcher 
explained to the participants any of the confused questions that were not clear to them. 
3.8.2 Pilot study  
A questionnaire was piloted with ten  patients and ten of control in order to check any 
additions or difficulties dealing with population; ten samples of patients and ten 
samples of control were collected and tested at the beginning of the study to evaluate 
the efficiency of the reagents and to optimize used techniques and to check any 
difficulties facing the researcher. 
  




3.8.3 Sample collection 
Five ml of fasting blood sample about 8-12 hours was taken from each subject, five ml 
of the blood were collected in a plain tube and the serum was obtained by centrifugation 
at 3000 rpm for 5 minutes. Serum were frozen at -20
ο
C till the determination the 
following biochemical parameters:- 
 Lipid profile ( Total triacylglycerol, total Cholesterol, LDL-c and HDL-c).  
  Apo C- III and Apo A1. 





Table 3.1 Chemicals and reagents used in the present study. 
Reagent Supplier 
Glucose Diasys Diagnostic Systems, Germany 
Aspartate transaminase Diasys Diagnostic Systems, Germany 
Lactate dehydrogenase Diasys Diagnostic Systems, Germany 
Creatinine kinase (CPK) Diasys Diagnostic Systems, Germany 
Creatinine kinase MB (CK-MB) Diasys Diagnostic Systems, Germany 
Total Cholesterol Diasys Diagnostic Systems, Germany 
Total triacylglycerols Diasys Diagnostic Systems, Germany 
HDL-C Diasys Diagnostic Systems, Germany 
LDL-C Diasys Diagnostic Systems, Germany 
Apolipoprotein C-ІІІ 
Kamiya Biomedical Company, United 
Kingdom 
Apolipoprotein A1 Diasys Diagnostic Systems, Germany 
Quality control 
Normal control (Chemistry) TruLabN, Germany 
Abnormal control (Chemistry) TruLabN , Germany 
Apolipoprotein Control level 1 
Kamiya Biomedical Company (K-
ASSAY), United Kingdom 
Apolipoprotein Control level 2 K-ASSAY, United Kingdom 
Apo AІІ/ CІІ/ CІІІ calibrator K-ASSAY , United Kingdom 















3.11 Statistical Analysis 
All the calculation were performed statistical Package for Social Sciences (SPSS) 
software version 21. Clinical data were expressed as mean±SD and difference between 
groups analysed by t-tests for continuous variable and chi square (
2
) test for categorical 
variable. Association between continuous variables were assessed with person 
correlation coefficient and between categorical variable by Mantel-Haenszel chi-square 
for trend. The results were presented through histogram, tables and charts, Statistical 
significance was set at P-values < 0.05. Frequencies, Percentage, cross tabulation and 
range as minimum and maximum value were applied. The percentage difference was 
calculated according to the formula: Percentage difference equals the absolute value of 
the change in value, divided by the average of the 2 numbers, all multiplied by 100. 
Percent difference = (| (V1 - V2) | / ((V1 + V2)/2)) X 100. 
Microsoft Excel program version 11.0 was used for correlation graph plotting. 
3.11.1 Diagrams used in the Statistical Analysis 
 Bar graphs 
 Ogive curve 
  
Reagent Supplier 
Spectrophotometer (semi-autoanalyser) Rayato, Germany 
Chemistry  auto-analyser  Mindray BS-120, China 
Centrifuge Elektro-mag, Turkey 
Water Bath LG, Korea 
Micropipettes Elektro-mag, Turkey 
Vortex Mixer Eppendorf, Germany 




3.12 Methods  
 
3.12.1 Body mass index (BMI) 
Body mass index is defined as the measurement of the relative percentages of fat and 
muscle mass in the human body, in which weight in kilograms is divided by height in 
squared meters and the result is used as an index of obesity. 
 
Table 3.3 Classification of BMI according to WHO (WHO, 2012) 
  
BMI 
underweight < 18.5 
Normal range 18.5 – 24.9 
Overweight  ≥ 25.0 
Preobese 25.0 – 29.9  
Obese ≥ 30.0 
Obese class  30.0 – 34.9 
Obese class  35.0 – 39.9 
Obese class  ≥ 40.0 
 
3.13 Laboratory investigations and clinical tests. 
All tests were measured from serum sample using enzymatic, turbidimetric and 
colorimetric methods. 
 
3.13.1 Determination of serum glucose 
Method 
―GOD-PAP―: enzymatic photometric method. 
Principle 
The level of glucose was measured after enzymatic oxidation of glucose by glucose 
oxidase GOD. The colorimetric indicator is quinoneimine, which is generated from 4-




aminoantipyrine and phenol by hydrogen peroxide under the catalytic action of 












 Wavelength:   500 nm 
 Optical path:1 cm 
 Temperature: 37oC 
 Measurement: Against reagent blank. 
 Ten µl of standard, sample and control were added in each corresponded tube 
to one ml of the reagent and mixed well. 
 The mixture was incubated for 10 min at 37oC.  
 The absorbance was measured within 60 min. 
Calculation 
        (     )   
         
          
                           
 
  
Reagent Concentration  
Phosphate buffer (pH 7.5) 250 mmol/l 
Phenol 5 mmol/l 
4-Aminoantipyrine 0.5 mmol/l 
Glucose oxidase (GOD) ≥ 15 ku/ 
Peroxidase (POD)   ≥ 1 ku/l 
Standard 100 mg/dl 




Reference value (Fasting blood glucose) 
Child 60 – 100 mg/dl 
Adult 70 – 115mg/dl 
 
3.13.2 Determination of serum total cholesterol 
Method  
―CHOD-PAP‖: enzymatic photometric method. 
  Principle 
Cholesterol was measured after the enzymatic hydrolysis and oxidation by cholesterol 
esterase (CHE) and cholesterol oxidase (CHO). The colorimetric indicator is 
quinoneimine which was generated from 4-aminoantipyrine and phenol by hydrogen 















Reagent Concentration  
Buffer (pH 6.7)   50 mmol/l 
Phenol 5 mmol/l 
4- Aminoantipyrine 0.3 mmol/l 
Cholesterol esterase (CHE) ≥ 200 u/l 
Cholesterol oxidase (CHO) ≥ 100 u/l 
Peroxidase (POD) ≥ 3 ku/l 
Standard 200 mg/dl                           





 Wavelength: 500 nm 
 Optical path: 1cm 
 Temperature: 37 ºC 
 Measurement: against reagent blank. 
 Ten µl of standard (sample or control) was added to one ml of working 
reagent and mixed well. 
 The mixture was incubated for 5 min at 37 ºC.  
 The absorbance was measured within 60 min. 
 
 Calculation 
            (     )   
         
          
                           






3.13.3 Determination of serum triacylglycerols 
Method 
 
Colorimetric enzymatic test using glycerol-3-phosphate-oxidase (GPO). 
 
Principle 
Triglycerides level was measured by the enzymatic action of  lipoprotein lipase to 
liberate the glycerol. In the presence of ATP and glycerol kinase (GK), the glycerol was 
converted to glycerol-3-phosphate. The glycerol-3-phosphate was then oxidized by 
glycerol phosphate oxidase (GPO) to yield hydrogen peroxide. The condensation of 
hydrogen peroxide with 4-chlorophenol and 4-aminophenazone (4-AA) in the presence 
of peroxidase (POD) were produced a red colour quinonimine dye . 
Child (desirable)      < 170 mg/dl 
Adult (desirable)     <200 mg/dl 




























 Wavelength: 500 nm. 
 Optical path: 1 cm. 
 Temperature: 37 ºC. 
 Measurement: Against reagent blank. 
 
Ten µl of standard (sample or control) was added to one ml of working reagent after 
mixing and incubating at 37 ºC for 5 min, the absorbencies of standard and samples 
against blank were measured. 
 
 
Reagent Concentration  
Cood's buffer (pH  7.2) 50  mmol/l 
4-Chlorophenol 4   mmol/l 
ATP 2   mmol/l 
Mg
2+
 15 mmol/l 
Glycerokinase (GK) ≥ 0.4 KU/I 
Peroxidase (POD) ≥  2  KU/I 
Lipoprotein lipase (LPL) ≥  2  KU/I 
4-Aminoantipyrine 0.5 mmol/l 
Glycerol-3-phosphate-oxidase (GPO) ≥ 0.5 KU/I 
Standard 200 mg/dl 





               (     )   
         
          
                           
Reference Value 
 
Child (desirable) 30 - 150 mg/dl 
Adult (desirable) Male 40 - 160 mg/dl 
Adult (desirable) Female 35  - 135 mg/dl 
High risk    > 400 mg/dl 
 
 








Chylomicrons, VLDL and LDL-C were precipitated by adding phosphotungstic acid 
and magnesium ions to the sample. HDL-C was left in supernatant after centrifugation, 














 Two hundred µl of standard (sample or control) was added to five hundred µl of 
the precipitation reagent and mixed well. 
Reagent (Mono-reagent Components) Concentration  
Magnesium chloride 1.4 mmol/l 
Phosphotungstic acid 8.6 mmol/l    
Cholesterol standard 200 mg/dl 




 The mixture was allowed to stand for 15 min at room temperature, and then 
centrifuged for 20 min at 4000 rpm.  
 
Cholesterol determination 
 Wavelength: 500 nm 
 Optical path: 1cm 
 Temperature: 37 ºC 
 Measurement: against reagent blank. 
One hundred µl of the supernatant of standard (sample or control) was added to one 
ml of the cholesterol reagent after mixing and incubating at 37 ºC for 5 min, the 
absorbencies of standard and samples against blank were measured. 
Calculation 
      (     )   
         
          












3.13.5 Determination of serum LDL-C 
 
LDL-C can be calculated using the empirical relationship of Friedewald (Friedewald et 
al., 1972). 
Principle 
The ultra-centrifugation measurement of LDL-C is time consuming and expensive and 
requires special equipment. For this reason, LDL-C is most commonly estimated from 
Child 37 – 75 mg/dl 
Adult Male 35 – 65 mg/dl 
Adult Female 35 – 80 mg/dl 
High risk of CHD ≤  35 mg/dl 




quantitative measurements of total and HDL-C and triglycerides (TG) using the  
empirical relationship of Friedewald , when triacylglycerols < 400 mg/dl as follows: 
LDL-C = Total Cholesterol - HDL-C - TG/5. 
 
3.13.6 Determination of serum LDL-C 
When triacylglycerols > 400 mg determent LDL by enzymatic method. 
 Method 
LDL-C is a homogeneous method without centrifugation steps for the direct 
measurement of LDL-cholesterol. In a first step, LDL was selectively protected while 
non-LDL-lipoproteins are enzymatically processed. In a second step, LDL was released 














Reagent Concentration  
R1 Good‘s buffer     pH 6.8  
Cholesterol esterase (CHE)  











Good‘s buffer          pH 7.0  
4-Aminoantipyrine  












 Wavelength: 600/700 nm 
 Optical path: 1 cm 
 Temperature: 37oC 
 Measurement: Against reagent blank. 
 three µl of calibrator (sample or control) was added to two hundred and eighty 
l of R1 reagent  
 three µl of distal water  was added to two hundred and eighty l of R1 reagent 
(blank), after mixing and incubating for 5 min at 37 ºC, initial absorbance of 
(calibrator/control/ sample) was read (A1), after addition seventy µl of R2 to 




A= [ (A2 – A1) sample or calibrator] – [( A2 – A1) blank] 
 
      (     )   
         
          




Desirable 130 mg/dl 
Borderline high risk 130 –160 mg 
High risk    > 160 mg/dL 
 
3.13.7 Determination of serum AST 
Method 
Level AST was determined by kinetic method (Optimized UV-test). 





AST was transferred an amino acid from aspartate to 2-oxoglutarate and form 
oxaloacetate which reduced to malate and NADH was oxidized to NAD
+
 in presence of 
malate dehydrogenase. 
 
Addition of pyridoxal-5-phosphate (P-5-P) stabilizes the transaminases and avoids 
falsely low values in samples containing insufficient endogenous P-5-P, e.g. from 














 Wavelength: 340 nm 
 Optical path: 1 cm 
 Temperature:37oC 
 Measurement: Against reagent blank. 
Reagent Preparation 
Mix 4 parts of R1 + 1 part of R2 (e.g. 20 mL R1 + 5 mL R2) = mono-reagent 
Reagent Concentration  
R1: TRIS             pH 7.65 110 mmol/L 
L-Aspartate  320 mmol/L 
MDH (malate dehydrogenase)   ≥ 800 U/L 
LDH (lactate dehydrogenase)  ≥ 1200 U/L 
R2: 2-Oxoglutarate  65 mmol/L 
NADH  1 mmol/L 
Pyridoxal-5-phosphate FS  
Good‘s buffer                     pH 9.6  100 mmol/L 
Pyridoxal-5-phosphate  13 mmol/L 




Stability: 4 weeks at 2 – 8 °C, 5 days at 15 – 25 °C, the mono-reagent must be protected 
from light. 
After mixing and incubating one hundred µl (control/sample) with one  ml of mono-
reagent at test temperature for 1 min. Initial absorbance (A1) was read and reading was 
repeated at constant intervals of 1 minute, for 3 minutes. 
Calculation 
From absorbance readings calculate A/min and multiply by the corresponding factor 
from below: 
A/min x factor = AST activity [U/L]            Factor 1745 
Reference value 
Men < 35 U/L 
 
 
3.13.8  Determination of serum LDH 
Method 
Level LDH was determined by kinetic method (Optimized UV test). 
Principle 
The enzyme LDH converted pyruvate to lactate while oxidized NADH to NAD
+
. The 
reaction was monitored kinetically at 340 nm by the rate of decrease in absorbance 
resulting from the oxidation of  NADH to NAD+ proportional to the activity of LDH 
present in the sample. 
 
  












 Wavelength: 340 nm 
 Optical path: 1 cm 
 Temperature: 37oC 
 Measurement: Against air. 
Reagent Preparation 
Mix 4 parts of R1 + 1 part of R2 (e.g. 20 mL R1 + 5 mL R2) = mono-reagent 
Stability: 5 weeks at 2 – 8 °C 
               8 days at 15 – 25 °C 
The mono-reagent must be protected from light. 
After mixing and incubating ten µl of (control/sample) with one ml of mono-reagent at 
test temperature for 1 min. Initial absorbance (A1) was read and reading was repeated at 
constant intervals of 1 minute, for 3 minutes. 
Calculation 
From absorbance readings calculate A/min and multiply by the corresponding factor 
from below: 
A/min x factor = LDH activity [U/L]            Factor 16030 
Reference value  
 




Reagent Concentration  
R1: N-Methyl-D-Glucamine    pH 9.5  1.10 mol/L 
L-Lactate  180 mmol/L 
R2: NAD+                                pH 4.5  200 mmol/L 




3.13.9 Determination of serum CPK 
Method 
Level CPK was determined by kinetic method (optimized UV-test)  
Principle 
CPK was catalysed the reversible transfer of phosphate from adenosine triphosphate 
(ATP) to creatine then using ATP to form glucose-6-phosphate in presence hexokinase 
(HK). Glucose-6-phosphate was reacted with NADP
+
 in presence of glucose-6-
phosphate dehydrogenase and rate of formation NADPH was measured at 340 nm, the 




















Reagent Concentration  
R1:  Imidazole                pH 6.5 
Glucose 














R2: Imidazole  
ADP 
 AMP  
Diadenosine pentaphosphate  


















 Wavelength: 340 nm 
 Optical path: 1 cm 
 Temperature: 37oC 
 Measurement: Against reagent blank (40 µl of  distilled water and 1 ml mono-
reagent). 
Reagent Preparation 
Mix 4 parts of R1 + 1 part of R2 (e.g. 20 mL R1 + 5 mL R2) = mono-reagent 
Stability: 3 weeks at 2 – 8 °C 
               2 days at 15 – 25 °C 
The mono-reagent must be protected from light. 
After mixing and incubating forty µl (control/sample) with one ml of mono-reagent at 
test temperature for 1 min. Initial absorbance (A1) was read and reading was repeated at 
constant intervals of 1 minute, for 3 minutes. 
Calculation 
From absorbance readings calculate A/min and multiply by the corresponding factor 
from below: 
A/min x factor = CPK activity [U/L]            Factor 4127 
 
Reference value 
Adult < 190 U/L 
 
  




3.13.10 Determination of serum CK-MB 
Method 
Level CK-MB was determined by kinetic method (Optimized UV test, for CPK with 
inhibition of CK-M isoenzymes by monoclonal antibodies. 
Principle 
Creatine kinase activity was measured in presence an antibody to the creatine kinase-M 
monomer which completely inhibited creatine kinase-MM but did not affect the B 
monomer activity of the creatine kinase-MB or creatine kinase-BB. Since creatine 
kinase-MB consists of equal M and B subunits, its measured activity was 50 % of that 
found in the absence of the antibody. The sample was first preincubated with reagent, 
which contains anti-M antibody. Creatine kinase-B monomer activity was then 
determined of creatine phosphate. In the reaction, the creatine kinase-B catalyzes the 
transfer of a phosphate group from the creatine phosphate substrate to adenosine 
diphosphate (ADP). The subsequent formation of adenosine triphosphate (ATP) was 
measured through the use of two coupled reactions catalyzed by hexokinase (HK) and 
glucose-6-phosphate dehydrogenase (G6PDH) which results in the production of the 
reduced form of β-nicotinamide adenine dinucleotide phosphate (NADPH) from β-
nicotinamide adenine dinucleotide phosphate (NADP), this change in absorbance was 














 Wavelength: 340 nm 
 Optical path: 1 cm 
 Temperature: 37oC 
 Measurement: Against reagent blank (40 µl of  distilled water and 1 ml mono-
reagent). 
Reagent Preparation 
Mix 4 parts of R1 + 1 part of R2 (e.g. 20 mL R1 + 5 mL R2) = mono-reagent, the 
mono-reagent must be protected from light. 
Stability: 2 weeks at 2 – 8 °C 
               24 hours at 15 – 25 °C 
After mixing and incubating forty  µl (control/sample) with one ml of mono-reagent at 
test temperature for 1 min. Initial absorbance (A1) was read and reading was repeated at 
constant intervals of 1 minute, for 3 minutes. 
  
Reagent Concentration  
R1:  Imidazole                 
Glucose 

















R2: Imidazole  
ADP 
 AMP  
Diadenosine pentaphosphate  
Glucose-6-phosphate dehydrogenase (G6P-DH) 













From absorbance readings calculate A/min and multiply by the corresponding factor 
from below: 
A/min x factor = CK-MB activity [U/L]       Factor 4127 
 
Reference value  
 
Adult < 24 U/L 
 




ApoA1 was measured after react with specific antibodies to apoA1 which present in 
sample. Endpoint determination of the concentration of Apo A1 via photometric 




 Wavelength: 580 nm (500 - 700 nm) 
 Optical path: 1 cm 
 Temperature: 37oC 
 Measurement: Against reagent blank. 
Reagent Concentration  
R1:  TRIS                                       pH 7.5  
Polyethylenglycol (PEG), detergents, stabilizers 
100 mmol/L 
R2: TRIS                                       pH 7.5  
Anti-human apolipoprotein A1 antibody (goat) with stabilizers 
 
100 mmol/L 




 Two µl of  sample and control were added in each corresponded tube to two 
hundred and fifty L of reagent R1. 
 Two µl of  distilled water and hundred and fifty L reagent R1 in blank tube. 
 Mixing and incubating for 3–5 min. Initial absorbance (A1) was read, then add 
fifty L reagent R2. 
 Mixing and incubating for 5 min, second absorbance (A2) was read. 
A = (A2 – A1) sample or calibrator 
Calculation 
The concentration of apolipoprotein A1 in unknown samples was derived from a 
calibration curve using an appropriate mathematical model such as logit/log. The 
calibration curve is obtained with 3 calibrators at different levels and NaCl solution (9 
g/L) for determination of the zero value. 
Calibrators and controls 
For the calibration of automated photometric systems the DiaSys TruCal Apo A1 
calibrator is used. for internal quality control a DiaSys TruLab L control is  assayed 
with each batch of samples. 
Reference value  
 
Men 110 – 170 mg/dL     (1.10 – 1.70 g/L) 
Women  120 – 190 mg/dL (1.20 – 1.90 g/L) 
 









Apo C- was measured after mixed with anti-human apo C-III antiserum, agglutination 
was caused by the antigen-antibody reaction. The turbidity is measured at 600 nm and 











 Wavelength: 600 nm  
 Optical path: 1 cm 
 Temperature: 37oC 
 Measurement: Against reagent blank. 
Apo C-III was measured using a fully automated turbidimetric immunoassay. The 
reagent was obtained from Kamiya Biomedical Company, United Kingdom and the 
procedure recommended by the manufacturer was implemented Mindray BS-120, 
Germany. Imprecision was assessed on two control sera with level 1 and level 2.  
Apolipoprotein AII / CII / CIII calibrators are used to make a multi-point calibration 
curve for determinate apoC-ІІІ concentration on Mindray BS-120. 
 
3.14.11.5.1Calibrators and Controls 
Apo C-ІІІ 
Control 
LEVEL 1 LEVEL 2 
MEAN (mg/dL) RANGE (mg/dL) MEAN (mg/dL) RANGE (mg/dL) 




R1:  Tri(hydroxymethyl)aminomethane  
Buffer Reagent  
R2: Antiserum Reagent  
Anti-human Apolipoprotein CIII goat antiserum 
 




Calibrator value  
Concentration of lyophilized serum, reconstituted with 1 mL of purified water 
(undiluted): 
Apo AII (mg/dL) Apo CII (mg/dL) Apo CIII (mg/dL) 










































4.1 General Characteristics of the study population 
The studied population composed of 178 males equally distributed between the cases 
and control. 
4.1.1 The distribution of the study population according to age 
The distribution of age of T2DM patients and controls are shown in Table 4.1 and 
Figure 4.1. (61.8%) of T2DM patients age in the range of 40-60 years and (57.3%) of 
control of the same age range, while (38.2%) of T2DM patients is > 61 years and 
(42.7%) of the control in the same range. The chi-square test showed non-significant 
difference between ages of control and cases (
2
=0.37, P=0.32).  
 



































4.1.2 Distribution of the study population by living area 
The living area of the study population was distributed into four regions. The 
percentage of sample collection was distributed as follows: North Gaza Strip (48.9 % 
controls, 29.8 % T2DM and 21.3 % T2DM+HD), Gaza city was 46.4 % controls, 31.9 
% T2DM, 21.7 % T2DM+HD, Middle Gaza Strip was (50 % controls, 20.0% T2DM 
and 30.0% T2DM+HD, South Gaza Strip was 55.8 % controls, 26.9 % T2DM, 17.3 % 
T2DM+HD, as shown in Table 4.2 and Figure 4.2. 




T2DM T2DM+HD Control 
Gaza City 
Count 22 15 32 69 
%  31.9% 21.7% 46.4% 100.0% 
Middle 
Count 2 3 5 10 
%  20.0% 30.0% 50.0% 100.0% 
North 
Count 14 10 23 47 
%  29.8% 21.3% 48.9% 100.0% 
South 
Count 14 9 29 52 
%  26.9% 17.3% 55.8% 100.0% 
Total 
Count 52 37 89 178 
%  29.2% 20.8% 50.0% 100.0% 
 
 
Figure 4.2 Distribution of the study population by the living area 




4.1.3 Social of the study population 
As indicated in Table 4.3, the analysis of the educational status of the study 
population showed that the university level was the highest among controls which 
represented 44.9% and 31.5% of the cases.  However, 24.7% and 38.2% of control 
and cases had finished secondary school , 28.1% of control, 23.6% of cases had 
finished preparatory school, and 2.2% of control, and 6.7% of cases are 
unenlightened. The difference between various educational levels of controls and 
cases was not significant (
2
=7.03, P=0.071). Also, 27% of cases were smokers 
compared with  20.2% of control. There is no significant relationship between 
smoking and non-smoking among case and control groups (2=1.122, P=0.290). In 
addition, 85.4% of T2DM patients and 76.4% of control do not do exercise while 




Table 4.3 Social characters of the study population 
General characteristics 










unenlightened 6(6.7%) 2(2.2%) 

2
 7.03 0.071 
preparatory 21(23.6%) 25(28.1%) 
secondary 34(38.2%) 22(24.7%) 
university 28(31.5%) 40(44.9%) 
Smoking 
Yes 24(27%) 18(20.2%) 

2
 1.122 0.290 
No 65(73%) 71(79.8%) 
Exercise 
Yes 13(14.6%) 21(23.6%) 

2
 2.327 0.127 
No 76(85.4%) 68(76.4%) 










4.2 Anthropometric measurements of the study population 
Table 4. 4 revealed the anthropometric measurement of the study population. The 
mean weight of the control was 81.1±9.4 kg compared to 87.7±14.1kg of the cases. 
The weight difference was significant (t=3.7 and P=0.001) with % difference=7.8% 
higher in the cases. There was no significant difference in the mean height of the 
cases compared with the controls (1.72±0.07 vs. 1.74±0.06 m respectively, % 
difference = -1.2, t=-2.3 and P=0.588). Therefore, the BMI of the cases was 
significantly higher than that of the controls (29.6±4.2 vs. 26.7±3.12 respectively, % 
difference=10.3, t=5.2 and P=0.022). 
 
































10.3 5.2 0.022 
*Kg: kilogram, ** m: meter. ***BMI: Body mass index: People with BMI=18.5–24.9 were 
considered to have normal weight, people with BMI=25.0–29.9 were classified overweight, 
people with BMI≥30.0 were considered obese (WHO, 2012). All values are expressed as 










4.3 Parameters of the study population 
4.3.1 Glucose level of study population 
As shown in Table 4.5, the mean value of glucose level among cases was significantly 
higher than the controls (168.4±69.4 vs. 87.8±9.15 t=10.85 respectively, % difference 
=62.9 and P=0.001). 
 

















62.9 10.85 0.001 
 
4.3.2 Lipid profile of study population 
Table 4.6 illustrates lipid profile of the study population. There was no significant 
difference in the mean level of cholesterol among the cases compared with the control 
(194±29 vs.182.4±22.6, t=3.01 , % difference =6.5, p=0.057). The mean level of 
triacylglycerols among the cases was significantly higher than the control 
(173.8±144.4 vs. 113.9±28.7,% difference=41.6, t=3.83 p=0.001). Also, the mean 
level of LDL-C among cases was significantly higher compared with controls 
(123.9±30.1 vs. 119.3±23.5, t=1.14, % difference =3.78, p=0.028). The mean level of 
HDL-C among controls was significantly higher than the cases (40.5±5.7 vs. 















































3.78 1.14 0.028 
 
4.3.3 Cardiac enzymes of study population. 
Cardiac enzymes of study population are presented in Table 4.7. The mean levels of 
cardiac enzymes (CPK, CK-MB, LDH and AST) among the cases were significantly 
higher  than the controls. The mean level of, CPK among the cases compared with the 
controls were (120.9±128.8 vs. 77.3±38,% difference=43.9, t=3.1 p=0.001). The CK-
MB level among the cases compared with the controls (20.1±15.6 vs. 
13.7±5.6 ,%difference=37.9, t=3.6, p=0.001), also the mean level of LDH in the 
studied cases was higher than the control (317±70.8 vs. 284±44,% difference=11.1, 
t=3.8, p=0.001). Finally, the mean level of AST in the cases were higher than the 
controls (22±12.6 vs. 18±4.9, % difference=2.8, t= 2.82, p=0.002. 
















43.9 3.1 0.001 






37.9 3.6 0.001 






11.1 3.8 0.001 






20.4 2.8 0.002 
 




4.3.4 Apo C- and Apo A1 levels of study population 
Table 4.8 shows the levels of apo C- and apoA1 of study population. The 
concentration of apo C- was significantly elevated in T2DM patients compared 
with the controls (13.71±8.52 vs. 6.4±1., t=7.85, %difference = 72.7, P=0.001). Also, 
ApoA1 level was significantly decreased in T2DM patients compared with the 
controls (1.03±0.56 vs. 1.32±0.19, %difference=-25.6, t=-4.79, p=0.001).  
 



























-25.6 -4.79 0.001 
 
4.4 Correlation between apo C-  and biochemical parameters  
4.4.1 Correlation between apo C- and glucose, cholesterol, 
triacylglycerols, HDL-C and LDL-C 
Table 4.9 and Figure 4.3 revealed that there is positive significant correlation between 
apo C-  and glucose level in T2DM patients (r=0.238, P=0.012) and not significant  
correlation in controls (r=0.156, P=0.072). Analysis of  association between Apo C- 
and cholesterol showed positive significant correlation in both T2DM patients and 
controls ( r=0.340, P=0.001 and r=0.208, P=0.026, respectively). The correlation 
between apo C- and triacylglycerols in all subject showed significant positive  
correlation in T2DM patients and control (r=0.755, P= 0.001 and r=0.426, P=0.001, 




respectively). There was not negative significant correlation between Apo C- and 
HDL-C in T2DM patients and controls (r=-0.009,  P=-0.486 and r=-0.105, P= -0.163). 
Finally the correlation between Apo C- and LDL-C was not negative significant in 
T2DM patients and not weak positive significant correlation in controls (r=-0.161,  
P=0.066 and r=0.113, P=0.145, respectively). 
 
Table 4. 9 The Correlation between apo C- and glucose, cholesterol, 
triacylglycerols, HDL-C and LDL-C . 
 
Parameter 









0.238 0.012* 0.156 0.072 
Cholesterol 
mg/dl 
0.340 0.001* 0.208 0.026* 
Triacylglycerols 
mg/dl 
0.755 0.001* 0.426 0.001* 
HDL-C 
 mg/dl 
-0.009 -0.486 -.105 -0.163 
LDL-C  
mg/dl 
-.161 0.066 0.113 0.145 
*P>0.05: not significant,  P<0.05: significant. 
                     







Figure 4.3 The Correlation between apo C- and glucose, cholesterol, 
triacylglycerols, HDL-C and LDL-C 
 




 4.4.2 Correlation between apo C- and cardiac enzymes. 
As illustrated in Table 4.10 and Figure 4.4, analysis of cardiac enzymes showed no 
significant correlation between apo C- and CPK among cases and controls (r=0.096, 
P=0.185 and r=0.055, P=0.303, respectively). Whereas, there is no significant 
correlation between apo C- and CK-MB among cases and significant weak positive 
correlation with controls (r=-.045, P=-0.045 and r=0.176, P=0.049, respectively). LDH 
results showed no significant correlation among cases and controls (r=0.094, P=0.191 
and r=-0.106, P=-0.161, respectively ). In addition the correlation between apo C- and 
AST showed significant correlation among cases and controls (r= 0.237, P=0.013 and  
r=0.198, P=0.031, respectively). Finally a significant correlation was found between apo 
C- and Apo A1 among cases (r=0.242, P=0.011) and no significant correlation with 
controls (r=-0.025, P=0.406). 
Table 4.10 Correlation between apo C- and cardiac enzymes. 
 
Parameter 









0.096 0.185 0.055 0.303 
CK-MB 
IU/L 
-0.045 -0.338 0.176 0.049* 
LDH 
IU/L 
0.094 0.191 -0.106 -0.161 
AST 
IU/L 
0.237 0.013* 0.198 0.031* 
ApoA1 
g/L 
0.242 0.011* -0.025 0.406 
*P>0.05: not significant,  P<0.05: significant. 
 
 





Figure 4.4 Correlation between apo C- and cardiac enzymes. 




4.5 Investigation of apo C- among T2DM groups and controls. 
As indicated in Table 4.11, ANOVA test showed significant difference of apo C-III 
level between the three groups (T2DM, T2DM+HD, control) with p-value=0.0001. 
There was a significant difference between the control and T2DM patient in favor of 
T2DM (mean difference =-9.78, P=0.001) and there was a significant difference 
between the control and T2DM+HD patients in favor of T2DM+HD patients (mean 
difference =-3.75, P=0.001). In addition, there was a significant difference between 
T2DM and T2DM+HD patients in favor of T2DM (mean difference=6.0, P=0.0001). 
 
Table 4.11 Investigation of apo C- tests among T2DM groups and controls. 
Status Variable F-stat P-value 
Between Groups 46.237 0.0001* 
      
Control 
 Mean Difference P-value 
DM -9.78 0.0001* 
DM+HD -3.75 0.001* 
DM DM+HD 6.0 0.0001* 
 
4.6 The distribution of cases according to heart disease. 
Figure 4.5 revealed the distribution of cases according to heart disease which was 
divided into two groups according to heart disease (with/without heart disease) [58% of 





Figure 4.5 Distribution of cases according to heart disease. 




4.7 The distribution of cases according to hypertension. 
The analysis of hypertension status among the cases showed that 78.4%of T2DM+HD 
and 50% of T2DM patients are suffering from hypertension (Table 4.12 and Figure 4.6). 
There is statistically significant difference between hypertensive and normotensive in 
T2DM and T2DM+HD groups. (2=7.37, P=0.006. 
 
Table 4.12 The distribution cases according to hypertension. 
 




T2DM 26 (50%) 26 (50%) 
7.37 0.006 T2DM+HD 29 (78.4%) 8 (21.6%) 
 
 
Figure 4.6 Distribution of cases according to hypertension. 
 
 
4.8 The distribution of cases according to type of treatment 
As indicated in Table 4.13, most T2DM (73.1% ) and T2DM+HD (64.9% ) patients 
were dependent on oral hypoglycemic agents , whereas 26.9% of T2DM and 35.1% of 
T2DM+HD patients were dependent on insulin injection. In addition, 21.2% of T2DM 
and 29.7% of T2DM+HD using lipid-lowering drugs. There is no statistically 




significant differences between types of treatment used (hypoglycemic agents and lipid-
lowering drugs) in the two groups (
2
=0.69, P=0.274 and. 
2
 =0.85, P=0.249. 
 
Table 4.13 Distribution of cases according to the type of treatment. 
 





Pill 38(73.1%) 24(64.9%) 
0.69 0.274 
Insulin 14(26.9%) 13(35.1%) 
Lipid-lowering 
agent 
Yes 11(21.2%) 11(29.7%) 
0.85 0.249 
No 41(78.8%) 26(70.3%) 
 
4.9 Biochemical characteristics of T2DM and  T2DM+HD patients. 
Table 4.14 revealed that there is no statistically significant difference in the mean value 
of serum glucose, LDL-C and Apo A1 level among T2DM and T2DM+HD patients . 
HDL, CPK, CK-MB and AST values were slightly different among T2DM and 
T2DM+HD patients with no statistically significant difference. In contrast, serum 
triacylglycerols was higher among T2DM compared with T2DM+HD with statistically 
significant difference (206±177 vs. 128±54, t=2.97, P=0.002 respectively). Moreover, 


















166±71 170±68 -0.264 0.847 
Cholesterol 
mg/dl 
200±31 186±23.8 2.34 0.243 
Triacylglycerols 
mg/dl 
206±177 128±54 2.97 0.002* 
HDL mg/dl 40±11.1 37±10.9 1.425 0.889 
LDL mg/dl 124±32 124±27 0.007 0.589 
CPK IU/L 115±125 129±135 -0.490 0.247 
CK-MB IU/L 19±14.6 21.5±17 -0.722 0.736 
LDH IU/L 330±79.3 299.7±52.8 2.02 0.125 
AST IU/L 24.5±14.8 19±7.4 2.183 0.055 
ApoA1 g/L 1.04±0.5 1.02±0.5 0.128 0.808 
Apo C- mg/dl  16.2±9.4 10.2±5.4 3.49 0.001* 
 
4.10 Glucose distribution according to DM duration. 
Glucose level was classified into three reference values: normal (70-115 mg/dl), high 
(116-200 mg/dl), and very high (>200 mg/dl). Table 4.15 and Figure 4.7  revealed that 
22.2% of T2DM and 33.3% of T2DM+HD who suffered from T2DM for 5 years have 
normal glucose, 55.6% of T2DM and 50% of  T2DM+HD have high level glucose and 
22.2% of T2DM and 16.7% of  T2DM+HD have very high level glucose. Whereas, 17.6 
% of T2DM and 19.4% of T2DM+HD who suffered from diabetes more than 5 years 
have normal glucose, 52.9%  of T2DM and 54.8% of T2DM+HD have high glucose 
level and 29.4% of T2DM and 25.8% of  T2DM+HD have very high glucose level.   
The two groups of cases who suffered from diabetes for more than 5 years have high 
glucose level which may increase the risk of  CVD complication among those patients. 


























































*GLUCOSE Normal Range:  70-115 mg/dl 
 
 
Figure 4.7 Glucose distribution according to DM duration. 
 
 
4.11 Apo C- distribution according to DM duration. 
Apo C- value was classified into two class intervals according to DM duration as 
shown in Table 4.16 and Figure 4.8. The percentages 22.2% of T2DM and 66.7% of 
T2DM+HD patients who suffered from diabetes for less than 5 years have a normal apo 
C- level while 77.8% of T2DM and 33.3% of T2DM+HD patients have high level of 
serum apo C-. However, 47.1% of T2DM  and 71.0% of T2DM+HD patients who 
suffered from diabetes for more than 5 years have a normal apo C- level, whereas 
52.9%of T2DM, and  29.0% of T2DM+HD have high apo C- level. 

































10.4-35 14(77.8%) 19(52.9%) 2(33.3%) 9(29.0%) 
Apo C- normal range 2.5-10.3 mg/dl 
 
 
Figure 4.8 Apo C- distribution according to DM duration. 
 
4.12 ApoA1 distribution according to DM duration. 
ApoA1 values were classified into three class intervals according to DM duration as 
shown in Table 4.17 and Figure 4.9. The percentages  38.9% of T2DM and 33.3% of 
T2DM+HD patients who suffered from diabetes for less than 5 years have a normal 
apoA1 level. However, 55.6% of T2DM and 66.7% of T2DM+HD patients have low 
level of serum apoA1. But, 41.2% of T2DM  and 25.8.0% of T2DM+HD patients who 
suffered from diabetes for more than 5 years have a normal apo C- level, whereas 
50.0% of T2DM, and  64.5% of T2DM+HD have low apoA1 level. 























































ApoA1 normal range 1.1 – 1.7 g/l 
 
 
Figure 4.9 ApoA1 distribution according to DM duration 
 
4.13 The association between Apo C- and BMI among cases 
BMI was classified into 2 classes intervals, normal BMI (18.5-24.9) and obese ≥ 30 
kg/m
2
 according to WHO (Table 4.18).  The mean level of apo C- in diabetic obese 
was significantly higher than in diabetic non-obese (14.4±8.8 vs. 9.8±5.2, t=-1.905and 
P=0.05). 
 





Table 4. 18. Association between Apo C- and BMI among cases 
 
BMI N Apo C- (mean ±SD) t-test P-value 
Normal 14 9.8±5.2 
-1.905 0.05 
Obese 75 14.4±8.8 
 
4.14 A Cumulative frequency distribution of data 
4.14.1 A cumulative frequency distribution of glucose 
Glucose measurements was classified into 6 class intervals (Table 4.19 and Figure 
4.10). The results showed that 19.2% of T2DM and 21.6% of T2DM+HD have normal 
glucose level, while 80.8% of T2DM and 78.4% of T2DM+HD have high glucose level. 
The highest percentage of T2DM patients was 38.5% and  27.0% of T2DM+HD 
patients , a located in the interval (124-161) which reflected slightly high level of blood 
glucose, while 26.9% of T2DM and 24.3% of T2DM+HD patients showed very high 
blood glucose >199 mg/dl. 






















































60-80 2 3.8% 3.8% 0 0.0% 0.0% 
81-115 8 15.4% 19.2% 8 21.6% 21.6% 
116-123 4 7.7% 26.9% 3 8.1% 29.7% 
124-161 20 38.5% 65.4% 10 27.0% 56.8% 
162-199 4 7.7% 73.1% 7 18.9% 75.7% 
200-400 14 26.9% 100.0% 9 24.3% 100.0% 
Total 52 100.0  37 100.0%  
* Glucose  Normal Range: 70-115 mg/dl 
 





Figure 4.10 A cumulative frequency distribution of glucose 
 
4.14.2 A cumulative frequency distribution of Lipid profile. 
Lipids profile tests (Total cholesterol (T.C), triglycerols, HDL-C , LDL-C) among the 
cases were compared using the a cumulative frequency distribution . 
A cumulative frequency distribution of cholesterol. 
Total cholesterol values were classified into 6 class intervals. The highest value of T.C 
among both cases groups was 301 mg/dl and the lowest value was 141 mg/dl. Our 
results revealed that T.C was within the normal range in 59.6 % of T2DM and 75.7% of 
T2DM+HD. Table 4.20 and Figure 4.11 showed that 2.7 % of T2DM+HD and 9.6% of 
T2DM crossed the high risk  of cholesterol level which may considered as a risk factor 




















































128-150 0 0.0% 0.0%% 2 5.4% 5.4% 
151-174 8 15.4% 15.4% 12 32.4% 37.8% 
*175-200 23 44.2% 59.6% 14 37.8% 75.7% 
**201-240 16 30.8% 90.4% 8 21.6% 97.3% 
***241-280 4 7.7% 98.1% 1 2.7% 100.0% 
281-350 1 1.9% 100.0% 0 0.0% 100.0% 
Total 52 100.0%  37 100.0  
* Cholesterol Normal Range: ≤ 200 mg/dl,**Borderline 200-240 
mg/dl 
*** High risk >240 mg/dl 
 
 
Figure 4.11 A cumulative frequency distribution of cholesterol. 
 
A cumulative frequency distribution of triacylglycerols. 
Triacylglycerol (T.G) value were classified into 6 class intervals as shown in Table 4.21 
and Figure 4.12. The percentages 73.0 % of T2DM+HD and 50% of T2DM patients 
have normal serum T.G, whereas 7.7% of T2DM and 18.9% of T2DM+HD patients 
were located in border high interval (151-199), whereas 42.3% of T2 DM and 8.1% of 




T2DM+HD were located in high risk interval (>200 mg/dl) and 3.8% of T2DM had 
very high level of T.G >800. 








































30-70 6 11.5% 11.5% 4 10.8% 10.8% 
*71-150 20 38.5% 50.0% 23 62.2% 73.0% 
**151-199 4 7.7% 57.7% 7 18.9% 91.9% 
***200-499 20 38.5% 96.2% 3 8.1% 100.0% 
***500-800 0 0.0% 96.2% 0 0.0% 100.0% 
***801-1000 2 3.8% 100.0% 0 0.0% 100.0% 
Total 52 100.0  37 100.0%  
*Triacylglycerols normal Range: ≤ 150 mg/dl, **Border high 
151-199mg/dl, ***High 200-499 mg/dl ***Very high>500mg/dl 
 
 
Figure 4.12 A cumulative frequency distribution of triacylglycerols. 
 
A cumulative frequency distribution of HDL-C. 
HDL-C values were classified into 6 class intervals. Table 4.22 and Figure 4.13 
revealed that HDL-C was below the normal range in 34.6% of T2DM and 43.2% of 




T2DM+HD, which may considered as a risk factor of arteriosclerosis and recurrent 
Myocardial infarction (MI) among T2DM+HD and T2DM patients. 
































































10-20 2 3.8% 3.8% 3 8.1% 8.1% 
21-30 9 17.3% 21.2% 8 21.6% 29.7% 
*31-34 7 13.5% 34.6% 5 13.5% 43.2% 
*35-45 17 32.7% 67.3% 14 37.8% 81.1% 
*46-55 13 25.0% 92.3% 5 13.5% 94.6% 
*56-65 4 7.7% 100.0% 2 5.4% 100.0% 
Total 52 100.0%  37 100.0%  
*HDL normal range >35 mg/dl 
 
 
Figure 4.13 A cumulative frequency distribution of HDL-C 
 
A cumulative frequency distribution of LDL-C. 
LDL-C values were classified into 6 class intervals as shown in Table 4.23 and Figure 
4.14. The percentages 69.2% of T2DM and 56.8 % of T2DM+HD patients were located 
in the normal range interval. The highest percentage of LDL-C among T2DM+HD 
patients were 43.2%  and 19.2% of T2DM patients which is located in the borderline 




interval (131-160). The percentages 11.5% of T2DM patients were located in a high risk 
interval (>160 mg/dl). 








































55-78 3 5.8% 5.8% 0 0.0% 0.0% 
79-100 6 11.5% 17.3% 7 18.9% 18.9% 
*101-130 27 51.9% 69.2% 14 37.8% 56.8% 
**131-160 10 19.2% 88.5% 16 43.2% 100.0% 
***161-200 5 9.6% 98.1% 0 0.0%  
***200-240 1 1.9% 100.0% 0 0.0%  
Total 52 100.0%  37 100.0  




Figure 4.14 A cumulative frequency distribution of LDL-C. 
 
 
4.14.3 A cumulative frequency distribution of Cardiac enzymes. 
Cardiac enzyme tests (CPK, CK-MB, LDH, AST, ApoA1) were compared together 
using a cumulative frequency distribution in two cases groups of the study. Elevation of 




serum levels of enzymes due to myocardial necrosis is considered to be a specific 
finding for myocardial infarction. 
 
A cumulative frequency distribution of CPK. 
CPK values were classified into 6 class intervals as shown in Table 4.24 and Figure 
4.15. The percentage 88.5% of T2DM and 78.4% of T2DM+HD patients were located 
in the normal range ( <170U/L).Whereas 18.9 % of T2DM+HD and 9.6% of T2DM 
patients were  at high risk interval (> 190U/L).  
 









































0-100 31 59.6% 59.6% 22 59.5% 59.5% 
*101-170 15 28.8% 88.5% 7 18.9% 78.4% 
**171-190 1 1.9% 90.4% 1 2.7% 81.1% 
***191-250 3 5.8% 96.2% 2 5.4% 86.5% 
251-700 1 1.9% 98.1% 4 10.8% 97.3% 
700-950 1 1.9% 100.0% 1 2.7% 100.0% 
Total 52 100.0%  37 100.0%  
*CPK normal range <170 U/L **Borderline 171-190U/L  
*** High risk of MI > 190 U/L   
 
 
Figure 4.15 A cumulative frequency distribution of CPK. 




A cumulative frequency distribution of CK-MB 
Creatine kinase MB values were classified into 6 class intervals (Table 4.25 and Figure 
4.16). Results showed that 71.2% of T2DM and 67.6% of T2DM+HD have normal CK-
MB level, whereas 32.4 % of T2DM+HD and 28.8% of T2DM patients were located at 
high risk interval (>24U/L). 
 









































0-15 27 51.9% 51.9% 18 48.6% 48.6% 
16-24 10 19.2% 71.2% 7 18.9% 67.6% 
25-35 8 15.4% 86.5% 6 16.2% 83.8% 
36-55 4 7.7% 94.2% 4 10.8% 94.6% 
56-65 3 5.8% 100.0% 1 2.7% 97.3% 
66-100 0 0.0%  1 2.7% 100.0% 
Total 52 100.0%  37 100.0%  




Figure 4.16 A cumulative frequency distribution of CK-MB 
 
 




A cumulative frequency distribution of LDH. 
LDH values were classified into 6 class intervals (Table 4.26 and Figure 4.17). Results 
showed that 94.2% of T2DM and 100% of T2DM+HD have normal LDH level. The 
percentages 5.8% of T2DM patients have high LDH level (>448), which may be 
considered as a risk factor of Heart disease in T2DM. 







































150-200 0 0.0% 0.0% 0 0.0% 0.0% 
201-250 5 9.6% 9.6% 7 18.9% 18.9% 
251-300 21 40.4% 50.0% 14 37.8% 56.8% 
301-448 23 44.2% 94.2% 16 43.2% 100.0% 
449-510 2 3.8% 98.1% 0 0.0%  
511-700 1 1.9% 100.0% 0 0.0%  
Total 52 100.0%  37 100.0%  
*LDH normal range <448  U/L 
 
 
Figure 4.17 LDH a cumulative frequency distribution ogaive  
 
  




A cumulative frequency distribution of AST 
Aspartate aminotransferase values were classified into 6 class intervals (Table 4.27 and 
Figure 4.18). Results showed that 90.4% of T2DM and 97.3% of T2DM+HD have 
normal AST level, whereas 9.6% of T2DM and 2.7% of T2DM patients have high level 
of AST enzyme (>35). 
 








































0-20 24 46.2% 46.2% 28 75.7% 75.7% 
20-30 20 38.5% 84.6% 8 21.6% 97.3% 
31-35 3 5.8% 90.4% 0 0.0% 97.3% 
36-46 1 1.9% 92.3% 0 0.0% 97.3% 
47-60 3 5.8% 98.1% 1 2.7% 100.0% 
61-110 1 1.9% 100.0%    
Total 52 100.0%  37 100.0%  
*AST normal range <35  U/L  
 
 
Figure 4.18 A cumulative frequency distribution of AST 
 




4.14.4 A cumulative frequency distribution of Apo A1 
Apolipoprotein A1 values were classified into 6 class intervals (Table 4.28 and Figure 
4.19). The percentages 48.1% of T2DM and 37.8% of T2DM+HD patients were located 
in normal interval (> 1.1), whereas 51.9% of T2DM and 62.2% of  T2DM+HD patients 
have low level of apo A1  which may considered as a risk factor of arteriosclerosis and 
thrombosis and myocardial infarction. 
 












































2.1-3.0 3 5.8% 5.8% 2 5.4% 5.4% 
1.71-2.0 1 1.9% 7.7% 1 2.7% 8.1% 
1.1-1.7 21 40.4% 48.1% 11 29.7% 37.8% 
0.51-1.09 23 44.2% 92.3% 21 56.8% 94.6% 
0.16-0.5 3 5.8% 98.1% 2 5.4% 100.0% 
0-0.15 1 1.9% 100.0% 0 0.0% 100.0% 
Total 52 100.0%  37 100.0%  




Figure 4.19 A cumulative frequency distribution of Apo A1. 
  




4.14.5 A cumulative frequency distribution of Apo C- 
Apo C- measurements were classified into 6 class intervals (Table 4.29 and Figure 
4.20. The percentages 38.5% of T2DM and 70.3% of T2DM+HD patients were located 
in normal interval (< 10.3), whereas  61.5% of T2DM and 29.7% of T2DM+HD 
patients have high level of apo C-  which considered as a risk factor of CVD.  
 









































0-2.4 0 0.0% 0.0% 0 0.0% 0.0% 
2.5-10.3 20 38.5% 38.5% 26 70.3% 70.3% 
10.4-15 12 23.1% 61.6% 8 21.6% 91.9% 
16-20 1 1.9% 63.5% 1 2.7% 94.6% 
21-30 14 26.9% 90.4% 1 2.7% 97.3% 
30-40 5 9.6% 100.0% 1 2.7% 100.0% 
Total 52 100.0%  37 100.0%  




Figure 4.20 A cumulative frequency distribution of Apo C- 




4.15. The association between hypoglycemic agents and biochemical 
parameters. 
As shown in Table 4.30, the mean concentration of plasma apo C-III was significantly 
elevated among diabetic patients who were used  pills as a drug of choice  compared 
with diabetic patients who were used insulin (14.5±8.9 vs. 12.0±7.2, P=0.039, 
respectively). Also, the mean concentration of  plasma triacylglycerols was significantly 
elevated among diabetic patients who were used pills compared with diabetic patients 
who were used insulin (186.4±167.2 vs. 144.6 ± 61.1, P=0.024, respectively). On the 
other hand, the mean concentration of apo A1 was significantly elevated among diabetic 
patients who were used  insulin as a drug of choice  compared with diabetic patients 
who were used pills (1.21± 0.67 vs. 0.95± 0.47, P=0.032, respectively). There was no 
statistically significant difference between diabetes type of treatment and  LDL-C,HDL-
C, total cholesterols, glucose, AST, CPK, CK-MB and LDH. 
  




Table 4.30  Association between hypoglycemic agent and biochemical parameters 
in cases group. 
Parameter Hypoglycaemic 
agent 
No Mean± SD t-test 
P-
Value 
Apo C- mg/dl 
Pill 62 14.5±8.9 
1.252 0.039* 
Insulin 27 12.0±7.2 
Apo A1 g/L 
Pill 62 0.95± 0.47 -
2.082 
0.032* 
Insulin 27 1.21± 0.67 
LDL-C mg/dl 
Pill 62 122±30.5 
-.693 0.766 
Insulin 27 127±29 
HDL-C mg/dl 
Pill 62 39.9±11.2 1.732 
 
0.920 
Insulin 27 35.5±10.3 
Triacylglycerols 
mg/dl 
Pill 62 186.4±167.2 
1.260 0.024* 
Insulin 27 144.6 ± 61.1 
Cholesterol mg/dl 
Pill 62 195.3±29.3 
0.519 0.315 
Insulin 27 191.8±29.1 
Glucose mg/dl 
Pill 62 165±69.3 -
0.695 
0.984 
Insulin 27 176 ±70 
AST  IU/L 
Pill 62 23.6± 13.8 
1.708 0.164 
Insulin 27 18.7± 8.3 
CPK IU/L 
Pill 62 124.7±145.4 
0.415 0.387 
Insulin 27 112.3± 80.2 
CKMB IU/L 
Pill 62 21.3±17.3 
1.143 0.088 
Insulin 27 17.2±10.6 
LDH IU/L 
Pill 62 319±79 
0.419 0.085 
Insulin 27 312± 47 
 
4.16  The association between lipid-lowering drugs and biochemical 
parameters. 
There were significant differences between lipid-lowering drugs and total 
cholesterol, triacylglycerols, AST and CPK level as shown in Table 4.31. On other 
hand, there is no statistically significant differences between lipid-lowering drugs 
and apo C-, apo A1, LDL-C, HDL-C, glucose, CK-MB and LDH.  
 




Table 4.31 Association between lower lipid and biochemical test in cases. 
Parameter Lower Fat No Mean± SD t-test P-Value 
Apo C- mg/dl 
Yes 22 15.5±9.8 
1.110 0.077 
No 67 13. ±8.1 
Apo A1  g/L 
Yes 22 0.95±0.32 
-0.823 0.070 
No 67 1.1±0.61 
LDL-C mg/dl 
Yes 22 119±36 
-0.877 0.214 
No 67 125±28 
HDL-C  mg/dl 
Yes 22 38.8±10.2 
0.092 0.512 
No 67 38.6±11.5 
Triacylglycerols mg/dl 
Yes 22 217±200 
1.634 0.046* 
No 67 159.6±118 
Cholesterol mg/dl 
Yes 22 193±40 
-0.174 0.027* 
No 67 194±24 
Glucose mg/dl 
Yes 22 161.5±61.8 
-0.540 0.440 
No 67 170±72 
AST  IU/L 
Yes 22 28.5±20.5 
2.87 0.000* 
No 67 19.9±7.6 
CPK  IU/L 
Yes 22 181.9±222.7 
2.64 0.000* 
No 67 100.8±68 
CKMB  IU/L 
Yes 22 18.8±14 
-0.417 0.745 
No 67 20.5±16.2 
LDH  IU/L 
Yes 22 331±91.8 
1.035 0.712 








































A rapidly rising of type 2 diabetes worldwide as well as in Gaza Strip portends a 
gloomy increase of CVD as the main complication of diabetes. The total number of 
people worldwide with T2DM was expected to increase from 171 million in 2000 to 
366 million in 2030 (Wild et al., 2004). Patients with T2DM have a much higher risk of 
stroke, with an increased risk of 150–400%. Risk of stroke-related dementia and 
recurrence, as well as stroke-related mortality, is elevated in patients with diabetes 
(Fowler, 2008). Metabolic imbalances such as hyperglycemia, dyslipidemia, and insulin 
resistance eventually lead to atherosclerosis through endothelial cell and vascular 
smooth muscle dysfunction combined with impaired platelet function and abnormal 
coagulation (Badran and Laher, 2012). Although extensive research has been conducted 
globally on diabetes mellitus, data on the disease is limited in the Gaza strip. The 
present study is the first to assess apo C-  levels among T2DM patients in the Gaza 
Strip. Understanding the status of apo C-III among T2DM patients could provide clear 
picture of the main complications of this disease and enable us to advise policy makers 









5.2 Characteristics of the study population 
5.2.1 Socio-demographic characters of the study population 
The distribution of the subjects by area showed that Gaza city has the highest rate of 
T2DM cases compared with other regions of Gaza strip, which could be due to the 
highest population present in Gaza city. However, the highest rate of T2DM+HD 
patients was from the southern and Gaza region, which could be due to geographical 
distribution, socioeconomic and environmental factors. Educational level of participant's 
revealed high rate of education among cases in Gaza Strip, in view of the fact that 
31.5% of the studied population have a university degree, 38.2% secondary school and 
the least education level was 30.3% for the preparatory school level and 6.7% 
unenlightened. May be higher educated participants are much aware of CVD risk 
factors and adopt more efficient preventive actions. 
 
5.2.2 Anthropometric measurements of the study population 
In the present study, the BMI and overweight of the cases were significantly higher than 
that of the controls which considered risk factors for heart disease that coincides with 
many studies reported obesity and overweight which were an independent risk factor for 
coronary heart disease (CHD), hypertension, angina, stroke and diabetes (Haffner, 2006; 
Poirier et al., 2006). BMI is frequently used as a surrogate measure of fatness in 
children and adults. 
  




5.3 Biochemical parameters of study population  
5.3.1 Glucose of the study population. 
Our results showed that glucose level was significantly higher in cases than controls, 
confirming the development of insulin resistance in type 2 diabetic patients. High 
glucose level cause short and long-term complication such as thirsty, weakness, urinate 
and infection. Long-term complication is associated with increased oxidative stress, 
enhanced leukocyte-endothelial interaction, and glycosylation of all  proteins in the 
body, including lipoproteins,  apolipoproteins, HbA1, albumin and clotting factors. 
Over time, through a complex series of dehydration and oxidation reactions, the 
formation of advanced glycosylation end products (AGEs) may occur. AGEs can induce 
excessive cross-linking of collagen and other extracellular matrix proteins, particularly 
in the vascular wall, which could lead to the accumulation of LDL particles. Moreover, 
AGE-modified LDL has a prolonged half-life, which contributes to the oxidation of 
LDL particles. AGEs may also promote atherothrombosis through their effect on 
endothelial cell function (Laakso, 1999). 
5.3.2 Lipid profile of the study population 
Triacylglycerols, LDL-C concentrations were statistically significantly higher in cases 
compared with the control and HDL-C concentrations were statistically significantly 
lower in cases compared with the controls. However, the difference in the total 
cholesterols level between cases and controls was not significant coincides with United 
Kingdom prospective diabetes study (UKPDS: 23) (Turneret al., 1998; Laakso, 1999; 
Mooradian, 2009). Elevated plasma levels of LDL-C, triglycerides (TG) and decreased 




HDL-cholesterol level are important contributors to premature coronary heart disease 
(CHD) in Patient with T2DM (Bos et al., 2003; Pollin et al., 2008).  
5.3.3 Cardiac enzymes of the study population 
Our results showed that cardiac enzymes (AST, CPK, CK-MB and LDH) were 
significantly increased among the cases which may considered as a predictor of the risk 
of near-term MI in diabetic patients compared with controls. Our study revealed that 
42% of diabetic patients were suffering from CVD due to complication of 
hyperglycemia. Serum enzymes such as CPK, LD, AST, and their isoenzymes have all 
been used as biomarkers of AMI, decades ago, they were thought to be sensitive 
indicators of myocardial necrosis and could be used to correlate with other signs and 
symptoms such as abnormalities in the ECG pattern. All these enzymes are found in 
other tissues as well, making them less specific to myocardial damage. AST, for 
example, is also found in skeletal muscle, liver parenchymal cells, and erythrocytes, 
while CPK is found in skeletal muscle, brain tissue, and embryonic or malignant tissue. 
LDH is the least specific of these three enzymes in that it is found in virtually all tissue 
and is associated with damage to liver, skeletal muscle, cardiac muscle, erythrocytes, 
renal cells, and many other tissues, as well as ovarian and testicular tumors. In order for 
these biomarkers to be more specific indicators of acute myocardial infarction, they 
were analyzed together several times a day over a period of 1 week. About third of 
T2DM+HD and T2DM patients were located at high risk interval (CK-MB>24U/L). As 
heart muscle damaged, CK-MB is released into the bloodstream and may be detected 
for 6 to 18 hours after onset of AMI, lasting no more than 12 to 18 hours after the heart 
attack occurred, because of protein degradation mechanisms that eliminate the CK-MB 
from the blood (Arneson and Brickell, 2007). 




5.3.4 Apo C- and apo A1 of the Study population 
Our study demonstrated a significant elevation of apo C- level among diabetic 
patients compared with controls, where 61.6% T2DM and 21.6% of T2DM+HD were 
showed high to very high level of Apo C-III. This means that very high rate of T2DM 
patients are may associated with insulin resistance, unregulated lipolysis, 
triacylglycerol-depleted remnant lipoproteins formation and under risk of the 
development of arteriosclerosis and further MI. High level of Apo C-III prevent the 
uptake of triacylglycerol-rich lipoprotein remnants by hepatic lipoprotein receptors, by 
the inhibit of  hepatic lipase and that both increased synthesis and reduced catabolic rate 
of apo C-III-rich particles may be involved in hyperlipidemia which were observed in 
our study cases with T2DM as one of the mean metabolic syndromes (Bobik, 2008). 
 
ApoA1 is a 243 amino-acid protein which, after synthesis, is secreted from the liver and 
the intestine. ApoA1 is the major protein constituent of human high density lipoproteins 
(HDLs) (60-70%), which play a key role in reverse cholesterol transport (RCT), 
shuttling excess of cholesterol from the circulation to the liver for catabolism (Ramella 
et al., 2011). ApoA1 was statistically significant decreased among diabetic patients 
compared with controls. Among our cases 51.9% of T2DM and 62.2% of  T2DM+HD 
patients have low level of apoA1  which may considered as a risk factor of 
arteriosclerosis, thrombosis and MI which is correlated with very high Apo C-III level 
observed among our cases. Such finding is coincided with that obtained by (Florvall et 
al., 2006). The association between cardiovascular morbidity and/or mortality and 
ApoA1 is in agreement with previous studies showing HDL-C superior to LDL-C as a 




risk marker for coronary artery disease and stroke in an elderly population (Weverling-
Rijnsburger et al., 2003). 
  
The ApoA1 concentration in plasma is usually strongly correlated with the amount of 
HDL-C (Florvall et al., 2006). ApoA1 is consistently protective against cardiovascular 
risk. In addition, both HDL and apoA1 have antioxidant, antithromobotic, and anti-
inflammatory properties, which could have important anti-atherogenic effects 
(Albahrani et al., 2007; Anantharamaiah et al., 2007).  
5.4 Method and reference interval for apo C-  in healthy Palestinian 
from Gaza strip 
Many different immunological techniques have been utilized for determination of apo 
C-, including electroimmunoassay , radioimmunoassay immunonephelometry and 
enzyme immunoassay (Ooi et al., 2008). These methods are time-consuming and not 
automated. Immunoturbidimetry is attractive because it can easily adapted to many 
spectrophotometric analyzers. In addition, these assays have the  advantage of allowing 
clinical laboratories to use commercially available antisera and standards (Rlfal and 
Silverman, 1986; Noma et al., 1991; Sakurabayashi et al., 2001).  We have established a 
reference intervals for the major apo CIII level in the Palestinian,  population using 
immune-turbidimetric assay, which is in agreement with other studies as shown Table 
5.1. Our present study, showed that the normal range of apo C- in healthy men in 
Gaza Strip is  6.4±3.9 mg/dl. 
  




Table 5. 1. Comparsion of apo C- levels with those in other population 
Reference n(subject) Level Apo C- mg/dl 
(Ashavaid et al., 2005) (Indian) 751 5.4-10.8 
(Sakurabayashi et al., 2001) (Japan) 2185 5.5-9.5 
(Noma et al., 1991) (Japan) 1144 5.6-10.2 
(Malati and Mahesh, 2009 ) (South Indians) 1923 7.7±3.2 mg/dl 
Our study  (Gaza Strip) 89 6.4±3.9 
 
5.5 Association between apo C- and biochemical parameters 
The Pearson correlation test in the present study showed positive correlations between 
apo C- and glucose (r=0.238,P=0.012) which is coincide with Caron et al., (2011) 
who suggested that in individuals with insulin resistance and diabetes, there is a loss of 
insulin-mediated suppression of apo C-III that, coupled with glucose-stimulated apo C-
III expression, leads to hypertriglyceridemia. In this study, we observed strong positive 
correlation of apo C-III with triacylglycerols and weak positive correlation with 
cholesterol (r=0.755,P=0.001, r=0.340, P=0.001 reciprocally) which is in agreement 
with other studies (Batal et al., 2000; Marcous et al., 2001; Hiukka et al., 2005), 
emphasize that patients with elevated levels of plasma triglycerols had increased plasma 
levels of apo C-III which is in agreement with (Dallinga-Thie et al., 2004). In healthy 
control subjects and hyperlipidemic patients, plasma triglycerides and apo C-III 
concentration were strongly correlated.  
In addition to the increased synthesis, a reduced catabolic rate of apo C-III–containing 
particles appears to contribute to the dyslipidemia observed in insulin-resistant 
individuals. Because apo C-III inhibits LPL-mediated triglyceride hydrolysis, a reduced 
catabolic rate of apo C-III–containing lipoproteins might be a major factor contributing 
to dyslipidemia in type 2 diabetes (Scheffer.et al., 2008). 




High plasma concentration of  apo C-III in LDL and VLDL particle strongly predicate 
recurrent coronary events in diabetic patients who had myocardial infarction (Lee et al., 
2003).  
5.6 Comparison between diabetes patients 
5.6.1. Hypertension 
Hypertension is a highly co-morbid condition in diabetic patients. In this study the 
prevalence of hypertension among T2DM with heart disease were higher than T2DM 
without heart diseases (78.4% vs.50% , P=0.006). This percentage is similar to other 
studies (Tai et al., 1991). Combination of diabetes and hypertension has increased the 
likelihood of the development of complications (Adle et al., 2000; Rahman and Zia, 
2004). 
5.6.2 Diabetes route of treatment 
By comparing the percentages of route of treatment in T2DM+HD and T2DM without 
HD patients, the results showed a higher use of insulin therapy and lipid lower therapy 
in T2DM+HD, 73.1% of T2DM was treated with hypoglycemic agent. Hypolipidaemic 
agents, particularly fibrates interfere with apo C- concentration because of their direct 
genomic effects through peroxisome proliferator-activated receptor (PPAR) a 
activation. Triacylglycerols, apo C- and Lp B:C3 concentrations were statistically 
significantly lower in T2DM patients receiving insulin treatment. This suggests that 
insulin therapy influences lipoprotein metabolism independently from glycaemic 
control. Such results are of particular interest because apo C- gene transcription is 
down-regulated by insulin (Gervaise et al., 2000). In our study, 21.2% of T2DM and 




29.7% of T2DM+HD patients were receiving antilipidemia treatment. In MOH, there is 
only one item of antilipidemia. Essential drug list and is rarely available in its clinics. In 
UNRWA, antilipidemia is not in the list of the drug that UNRWA makes available, but 
only few quantity of antilipidemia drug is available for certain patients under specific 
conditions, specially patients with heart disease in order to decreases complication and 
recurrent myocardial infarction. 
5.7 Diabetes  duration and apo C-  
In this study we demonstrated that more than half of patients had diabetes since less 
than 5 years, which confirm the idea that T2DM has a long asymptomatic preclinical 
phase which frequently goes undetected. Among people with T2DM, the proportion 
who are undiagnosed ranges from 30 to 90 % and by the time that they are diagnosed, 
complications has already taken place(Ramos and Isip-Tan, 2010).  The results of a 
number of studies have shown that individuals with T2DM have a risk of myocardial 
infarction (MI) within 8 years after diagnosis, comparable to that of nondiabetic 
individuals with previous MI from reinfarction (Muacevic-Katanec and Reiner, 2011). 
In Table 4.15, the present result confirmed the importance of self-monitoring of blood 
glucose (SMBG) which  can help both patients and their healthcare treatment of 
hyperglycemia in order to prevent or slow the progression of long-term microvascular 
complications of T2DM patients (Henry, 2001). 
Our study showed that 77.8% of T2DM without heart disease who are suffering from 
diabetes for less than 5 years had higher apo C- level more than T2DM+HD which 
put them under high risk MI and HD. In addition, the present data showed that treatment 
of patients with insulin and lipid-lowering agent is higher among T2DM+HD, that 




contribute to decrease apo C- level because insulin and lipid-lowering drug inhibit the 
synthesis of apo C- which is in agreement with other studies. Chen et al.,(1994) 
demonstrated that hepatic apo C- mRNA levels are elevated in insulin-deficient 
diabetic mice and that these levels are lowered after insulin treatment and Ginsberg and 
Brown, (2011),  reported that in the state of  insulin resistance, any inhibitory role of 
insulin on apo C-ІІІ expression may be lost, whereas higher glucose levels as in T2DM 
patients would further stimulate apo C-ІІІ expression. Those findings are  in coincide 
with data presented of present study in which  a statistically significant differences 
between insulin therapy and apo C- and apo A1 level were detectable.  
5.8 ApoA1 duration 
Our study showed that more than half of T2DM+HD patients who are suffering from 
diabetes for less than 5 years had lower apoA1 level than T2DM from the same disease 
duration. The percentages 64.5% of T2DM with heart disease who suffered from 
diabetes for more than 5 years have lower apoA1level than T2DM without heart disease 
from the same disease duration. These results put  T2DM without heart disease early 
diagnosed at higher risk of MI than patients under treatment for more than 5 years, but 
both of them still at high risk of MI and reflect the importance of a good care program 
in Palestine in monitoring T2DM+HD. We found that HDL-C was below the normal 
range in 34.6% of T2DM and 43.2% of T2DM+HD and LDL-C values among 
T2DM+HD patients were 43.2%  and 19.2% of T2DM patients which is located in the 
borderline interval (131-160). In present study 11.5% of T2DM patients were located in 
a high risk interval (>160 mg/dl). These result reflected the important of ApoA1 as a 




sensitive  predicting factor of CHD and immature MI more than HDL and LDL , these 
results are in agreement with other studies (Andrikoula and McDowell. 2008).  
5.9 Comparison between cases  according biochemical parameters 
5.9.1 Glucose 
Our data shows a highly uncontrolled glycemia among diabetic patients without heart 
disease (80.8%)  which also higher than diabetic patients with heart disease (78.4%). 
This conclusion can be interpreted as very inadequacy in the glycemic control among 
diabetic patients either by education or pharmacological intervention. Moreover, most 
diabetic patients in this study are with diabetes duration of more than ten years, and 
diabetes duration influences glucose level directly which agreement with (Gloria-
Botthini et al., 2000). 
5.9.2 Lipid 
When considering values of cholesterol ranging between 200-239 mg/dl as the 
borderline risk group and >240 mg/dl as the high-risk group for CHD, as considered by 
the National Cholesterol Education Program (NCEP), our T2DM  patients showed that 
30.8% of T2DM and 21.6% of T2DM+HD were in the borderline risk group, while 
9.6% of T2DM and 2.7% of T2DM+HD fell in to the high-risk group. With 
triacylglycerols estimation, the borderline (>150 mg/dl) and high-risk group (>200 
mg/dl) for CHD were 36.5% and 5.7%, respectively, in T2DM, and 8.1% and 0.0%, 
respectively, in the T2DM+HD. In addition, 19.2% of T2DM and 43.2% of T2DM+HD 
fall into borderline group of LDL-c level and 11.5%, 0.0% of T2DM+HD were fell into 
high LDL-C risk group. Lower percentage of high risk of cholesterol and LDL-C among 
T2DM+HD  than T2DM may be result of protective drug used by T2DM+HD as lower 




lipid drug which reduced risk of recurrent MI. It has been well documented that high 
levels of cholesterol and LDL play a significant role in the development of 
arteriosclerosis. So management of dyslipidemia in our diabetics must receive more 
attention, as these patients are already at higher risk of CVD. It has been suggested that 
using lipid-lowering agents is very important and to be more effective and cost-effective 
than treating hyperglycemia (Vijan and Hayward, 2004).  
Results showed that  34.6%  of T2DM and 43.2 % of T2DM+HD had low HDL level 
and were fell into high risk group .  In NCEP Adult Treatment Panel III (ATP III) 
guidelines, Low HDL (≤40 mg/dl) is one of 5 major CHD risk factors (Assmann and 
Gotto, 2004). The HDL particles induce the removal of cholesterol from cells, including 
those in atherosclerotic plaques, and carry them to the liver, but the mechanisms by 
which HDL confer protection from atherosclerosis include more than just reverse 
cholesterol transport. HDL particles seem to have anti-inflammatory and antioxidant 
properties, inhibiting the oxidation of LDL cholesterol and the expression of cellular 
adhesion molecules and monocyte recruitment. The HDL may also reduce the risk of 
thrombosis by inhibiting platelet activation and aggregation (Bizur et al., 2009). 
5.9.3 Cardiac enzymes  
Higher myocardial enzyme peak serum levels were related to increased severity of CAD 
(Peppes et al., 2008). Our results reveal that CPK was within high risk range in 9.6% of 
T2DM and 18.9% of T2DM+HD patients, whereas in a cumulative frequency 
distribution of CK-MB showed that 28.9% of T2DM and 32.4% of T2DM+HD patients 
were within high risk range >24U/L. Which may indicate that some of T2DM suffer 
from CVD complication but until now not diagnosed. So management of cardiac 




enzymes in our diabetics must receive more attention, as these patients are already at 
higher risk of CVD. 
Elevation of CPK can be associated with many conditions but primarily cardiac and 
muscle diseases. Myocardial injury usually results in CK-MB levels higher than 5% of 
total CPK in the blood whereas skeletal muscle injury results in CK-MB levels lower 
than 5% of total CPK. There are several causes of elevation of CK-MB as extreme 
physical activity, hypothyroidism, false elevations of CK-MB may also be seen in 
chronic dialysis patients and malignancies (Mannem et al., 2009). 
5.9.4 Apolipoprotein A1 
HDL-C and apoA1 levels are characteristically reduced in insulin-resistant people, 
fractional catabolism of apoA1 is increased in T2DM with low HDL-C as it is in 
nondiabetics with similar lipoprotein profiles (Ginsberg et al., 2005). ApoA-I stimulates 
the activity of ABCA1 and LCAT. It further affects HDL catabolism as the ligand for 
membrane-bound receptors and selective cholesteryl ester uptake by SR-B1 (Desroch et 
al., 2008). In present study, 51.9% of T2DM and 62.2 % of T2DM+HD patients have 
low apoA1levels which may demonstrated that ApoA1 is the strongest risk marker for 
CVD in diabetics men either with or without heart diseases and the mortality is in 
agreement with the increased evidence that HDL-based therapy effectively prevents 
CVD. which is coincide with Sorci-Thomas et al., (2002)  Low level of HDL-C and 
ApoA1 are highly correlated with CVD risk among T2DM patient.  
5.9.5 Apolipoprotein C-  
This case-control study demonstrated higher concentration of apo C-III in subjects with 
T2DM in which, 61.5% of T2DM and 29.7% of T2DM+HD fell at high risk group of 




high Apo-CIII level (10.4-40 mg/dl).  which may associate with increased severity of 
CVD in subjects with angiographically defined coronary artery disease (Koren et al., 
1996), with the metabolic syndrome (Onat et al., 2003). The results of large clinical 
studies have indicated  that  sera apo C- concentrations were a better  predictor  
of risk for the development and progression of CHD than  the traditionally  
measured  TG levels (Yu et al., 2011).  
 A growing body of evidence indicates that apo C-III is a multifunctional protein that 
not only regulates the metabolism of triglyceride-rich lipoproteins; it is also an 
important regulator of endothelial function. Its ability to induce endothelial dysfunction 
links hyperlipidemia with endothelial cell dysfunction and is one mechanism by which 
triglyceride-rich lipoproteins may augment inflammatory responses associated with 
developing atherosclerotic lesions, thereby increasing the risk for atherosclerotic 
cardiovascular disease (BobiK, 2008). 
5.10 Association between Apo C- and BMI among cases 
Apo C- in diabetic obese was significantly higher than in diabetic non-obese. Obesity 
is associated with several conditions, the most devastating of which may be T2DM. In 
obese individuals, adipose tissue releases increased amounts of non-esterified fatty 
acids, glycerol, hormones, proinflammatory cytokines and other factors that are 
involved in the development of insulin resistance (Kahn et al., 2006). The results of this 
study demonstrated elevated apo C- level among obese diabetes compared with non-
obese diabetes. Obese men with insulin resistance were demonstrated to have higher 
concentrations of plasma apo C-III and triacylglycerol-rich lipoproteins and a lower 
estimated fractional catabolic rate of these particles. Insulin resistance increases hepatic 




synthesis of lipid substrates and the secretion of VLDL apoB-100 , it also down 
regulates LDL receptors. Moreover, increased apo C-III inhibits the lipolysis of VLDL-
triglycerides by lipoprotein lipase and interferes with the hepatic uptake of TRL 
remnants by LDL receptors (Chan et al., 2002). These effects potentially increased risk 




































The findings of this study reflect the importance of apolipoprotein C- as non-invasive 
tests to find T2DM patients who are at risk to develop CVD. The current study showed 
that concentration of apo C- level in 89 T2DM patients were significantly elevated, 
and may play a role in prognosis of CVD complication. So estimation of this marker is 
of interest for management and follow-up of such patients. 
1) Significant difference was found in the means of biochemical parameters 
between the patients and control groups.  
2) Obesity and overweight were found to be significantly associated with diabetes, 
as they considered as risk factors for T2DM. 
3) Significant correlation was found between apo C- and glucose, cholesterol, 
triacylglycerol, apoA1 and AST. 
4) The mean of apo C- in T2DM and T2DM+HD patients were higher than 
controls, and the mean of apo C- in T2DM patients is higher than in 
T2DM+HD, which consider risk factor for CVD. 
5) Hypertension is one of the risk factor for CVD, which play a role for 
accelerating CAD. 
6) The mean of triacylglycerols in T2DM patients is higher than T2DM+HD, 
which may increase the risk of  CVD complication among those patients. 
7) Higher concentration of apo C- was found among T2DM patients  who 
suffered from diabetes for less than 5 years than T2DM patients who suffered 
from diabetes for more than 5 years. 
8) The mean of apo C- in obese diabetes was higher than non-obese diabetes.  




9) Apo AI is significantly decreased among T2DM patients more than controls. 
6.2 Recommendations 
1) There is a need to improve the diabetic patients' and general populations' 
awareness of diabetic complications, cardiovascular risk factors and the 
importance of lifestyle modifications. This could be achieved by improving 
patients' counselling by health care, or through campaigns and media to aware 
general populations. 
2) In the MOH and UNRWA diabetes clinics, only glucose, triacylglycerols and, 
cholesterol are used to evaluate diabetic patients. Other important measures as 
apo C- and apo A1 are recommended to be measured. 
3) Measurement of LDL and HDL are not applied to screening T2DM in the 
MOH and UNRWA diabetes clinics, thus those test should be used as routine for 
screening all patients under risk of CVD. 
4) Sustainable availability of expensive dyslipidemia medications are rarely 
achieved in MOH and never in UNRWA. So we recommend more attention 
from the decision makers about the problem of dyslipidemia in diabetic patients 
and the availability of medications. 
6.2.2. Recommendations for future research 
1) Further research is needed to investigate the changes in the different variables and 
apo C- among T1DM patients. 
2) Further research is needed to investigate the changes in the different variables and 
apo C- among female T2DM patients. 




3) Investigate the effect of apo C- on the gestational DM for pregnant women and 
influencing factors during pregnancy. 
























Aalto K., Weinstock H., Bisgaier L., Wu L., Smith D., and Breslow L (1996), 
Further characterization of the metabolic properties of triglyceride-rich lipoproteins 
from human and mouse apoC-III transgenic mice., The Journal of Lipid Research, 
37, 1802–1811. 
 
Adle I., Stratton M., Neil A., Yudkin S., Mathews R., and Cull A (2000), 
Association of systolic blood pressure with macrovascular and microvascular 
complications of type 2 diabetes (UKPDS 36): Prospective observational study, 
British Medical Journal, 321(7258), 412-419. 
 
Ahmed K., Muniandy S., and Ismail I (2010), Type 2 diabetes and vascular 
complicaions: A pathophysiologic view, Biomedical Research, 21(2), 147-155. 
 
Alaupovic P., Tavella M., and Shafer D (1992). Identification of apoB-containing 
lipoprotein families in NIDDM Diabetes, Diabetes, 41(2), 18-25. 
 
Albahrani A., Usher J., Alkindi M., Marks E., Ranganath L., and Al-yahyaee S 
(2007), ApolipoproteinA1-75 G/A (M1-) polymorphism and lipoprotein(a); Anti- 
vs. Pro-Atherogenic properties, Lipids in Health and Disease, 6(19). 
 
Altomonte J., Cong L., Harbaran S., Richter A., Xu J., Meseck M., and Dong H 
(2004). Foxo1 mediates insulin action on apoC-III and triglyceride metabolism, The 
Journal of Clinical Investigation, 114, 1493–1503. 
 
Anantharamaiah G., Mishra V., Garber D., Datta G., Handattu S., 
Palgunachari M., and Chaddha M (2007), Structural requirements for 
antioxidative and anti-inflammatory properties of apolipoproteinA-I mimetic 
peptides, Journal of Lipid Research, 48, 1915-1923. 
 
Andrikoula M., and McDowell W (2008), The contribution of ApoB and ApoA1 






Arneson W., and Brickell J (2007), Clinical chemistry a laboratory perspective, 
edited by Fratantoro.A, pp. 271-272, the United States of America.  
 
Ashavaid T., Kondkar A., Todur S., Dherai A., Mrey J., and Raghavan R 
(2005), Lipid, lipoprotein, apolipoprotein and lipoprotein(a) levels: Reference 
intervals in a Healthy Indian Population, Journal of Atherosclerosis and 
Thrombosis, 12(5), 251-259. 
 
Assmann G., and Gotto A (2004), HDL cholesterol and protective factors in 
atherosclerosis, The Journal of American Heart Association, 109, III-8 –III-14. 
 
American Diabtes Association (ADA), (2000), Screening for type 2 diabetes, 
Diabetes Care, 27, S11-S14. 
 
American Diabtes Association (ADA), (2004), Diagnosis and classification of 
diabetes mellitus, Diabetes Care, 27, S5-S10. 
 
Badran M., and Laher I (2012), Type II diabetes mellitus in arabic-speaking 
countries, International Journal of Endocrinology, 2012, 1-11. 
 
Balasubramaniam K., Viswanathan G., Marshall S., and Zaman A (2012), 
Increased atherothrombotic burden in patients with diabetes mellitus and acute 
coronary syndrome: a review of antiplatelet therapy, Cardiology Research and 
Practice, 2012, 1-18. 
 
Batal R., Tremblay M., and Barrett H (2000), Plasma kinetics of apoC-III and 
apoE in normolipidemic and hypertriglyceridemic subjects, Journal of Lipid 
Research, 41, 706–718. 
 
Bays H., Neff D., Tomassini J., and Tershakovec A (2008), Ezetimibe: 
Cholesterol lowering and beyond, Expert Review of Cardiovascular Therapy, 6(4), 
447-470. 
 
Bizur R., Cohen H., Kamari Y., Shaish A., and Harats D (2009), Triglycerides 





Blankenhorn D., Alaupovic P., Wickham E., Chin H., and Azen S (1990), 
Prediction of angiographic change in native human coronary arteries and 
aortocoronary bypass grafts lpid and nonlipid factors, The Journal of American 
Heart Association, 81, 470-476. 
 
Bobik A (2008), Apolipoprotein CIII and Atherosclerosis Beyond Effects on Lipid 
Metabolism, The Journal of American Heart Association, 118, 702-704. 
 
Bos G., Dekker M., Nijpels G., Vegt F., Diamant M., Stehouwer C., Bouter L., 
and Heine R (2003), A combination of high concentrations of serum triglyceride 
and non-high-density-lipoprotein-cholesterol is a risk factor for cardiovascular 
disease in subjects with abnormal glucose metabolism—The Hoorn Study, 
Diabetologia, 46, 910–916. 
 
Brunzell J., Davidson M., Furberg C., Goldberg R., Howard B., Stein J., and 
Witztum J (2008), Lipoprotein management in patients with cardiometabolic risk, 
Diabetes Care, 31(4). 
 
Caron S., et al. (2011), Transcriptional activation of apolipoprotein CIII expression 
by glucose may contribute to diabetic dyslipidemia, Arterioscler Thromb Vasc Biol, 
31, 513–519. 
 
Chan A (1998), Vitamin E and atherosclerosis, Nutritional, 128, 1593–1596. 
 
Chan C., Watts G., Barrett P., Mamo J., and Redgrave T (2002), Markers of 
triglyceride-rich lipoprotein remnant metabolism in visceral obesity, Clinical 
Biochemistry journal, 48, 278–283. 
 
Chen M., Bredow J., Li W., and Leff T (1994), Transcriptional regulation of the 
apoC-Ill gene by insulin in diabetic mice: Correlation with changes in plasma 
triglyceride levels, Journal of Lipid Research, 35, 1918-1924. 
 
Chhabra S., Narang R., Lakshmy R., Vasisht S., Agarwal D., Srivastava L., 
Manchanda S., and Das N (2004), Apolipoprotein C3 SstI polymorphism in the 





Christopher P (2007), Cardiovascular disease and modifiable cardiometabolic risk 
factors, Clinical Cornerstone, 8(3), 11-28. 
 
Claudel T., Inoue Y., and Barbier O (2003), Farnesoid X receptor agonists 
suppress hepatic apolipoprotein CIII expression, Gastroenterology 125, 544–555. 
 
Clavey V., Lestavel-Delattre S., Copin C., Bard M., and Fruchart C (1995), 
Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and 
apolipoproteins CI, CII, CIII, and E, Arterioscler Thromb Vasc Biol, 15(7), 963-971. 
 
Cohn J., Patterson B., Uffelman K., Davignon J., and Steiner G (2004), Rate of 
production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III 
is strongly related to the concentration and level of production of VLDL triglyceride 
in male subjects with different body weights and levels of insulin sensitivity, The 
Journal of Clinical Endocrinology & Metabolism, 89, 3949-3955. 
 
Cohn J., Batal R., Tremblay M., Jacques H., Veilleux L., Rodriguez C., Mamer 
O., and DavignonJ (2003), Plasma turnover of HDL apoC-I, apoC-III, and apoE in 
humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism, 
Journal of Lipid Research, 44, 1976-1983. 
 
Creager M., Luscher T., Cosentino F., and Beckman J (2003), Diabetes and 
vascular disease: pathophysiology, clinical consequences, and medical therapy: Part 
I, The Journal of American Heart Association, 108(12), 1527–1532. 
 
Dallinga-Thie M., Berk-Planken I., Bootsma H., and Jansen H (2004), 
Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing 
lipoprotein and HDL in type 2 diabetes: A potential mechanism to lower plasma 
triglycerides , Diabetes Care, 27, 1358–1364. 
 
Davidson H and Toth P (2007), High-density lipoprotein metabolism: potential 






Desroches S., Ruel L., and Deshaies Y (2008). Kinetics of plasma apolipoprotein 
C-III as a determinant of diet-induced changes in plasma triglyceride levels, Journal 
of Clinical Nutrition, 62, 10-17. 
 
Dijk K., Rensen P., Voshol P., and Havekes L (2004), The role and mode of 
action of apolipoproteins CІІІ  and AV: Synergistic actors in triglyceride 
metabolism?, Lipidology, 15, 239-246. 
 
Dokken B (2008), The Pathophysiology of cardiovascular disease and diabetes: 
beyond blood pressure and lipids, Diabetes Spectrum, 21(3), 160-165. 
 
Esther O., Barrett P., Chan D., and Watts G (2008), Apolipoprotein C-III: 
Understanding an emerging cardiovascular risk factor, Clinical Science, 114, 611-
624. 
 
Fernandez L., Metghalchi S., Vega-Lopez S., Conde-Knape K., Lohman G., 
and Cordero-Macintyre R (2004), Beneficial effects of weight loss on plasma 
apolipoproteins in postmenopausal women, The Journal of Nutritional 
Biochemistry, 15, 717-721. 
 
Fielding E., and Fielding J (Eds.) (2002), Dynamics of lipoprotein transport in the 
human circulatory system, 4th ed., pp 527–552. 
 
Florvall G., Basu S., and Larsson A (2006), Apolipoprotein A1 Is a stronger 
prognostic marker than are HDL and LDL cholesterol for cardiovascular disease and 
mortality in elderly men, Journal of Gerontology: Biological Sciences, 61A(12), 
1262–1266. 
 
Fowler M (2008), Microvascular and macrovascular complications of diabetes, 
Clinical Diabetes, 26(2), 77-82. 
 
Friedewald W., Levy R., and Fredrickson D (1972), Estimationof the 
concentrationof low-density lipoprotein cholesterolin plasma,without use of the 





Gangabadage C., Zdunek J., Tessari M., Nilsson S., Olivecrona G., and 
Wijmenga S (2008), Structure and dynamics of human apolipoprotein CIII, Journal 
of Biological Chemistry, 283(25), 17416-17427. 
 
Geesje D., Martin G., Richard B., Tjerk B., and Eric K (2001), Genetic 
heterogeneity in the apolipoprotein C-III promoter and effects of insulin, Journal of 
Lipid Research, 42, 1450-1456. 
 
Gerritsen G., Rensen C., Kypreos E., Zannis I., Havekes M., and W  van K 
(2005), ApoC-III deficiency prevents hyperlipidemia induced by apoE 
overexpression, The Journal of Lipid resesrch, 46, 1466–1473. 
 
Gervaise N., Garrigue A., Lasfargues G., and Lecomte P (2000), Triglycerides, 
apo C3 and Lp B:C3 and cardiovascular risk in Type II diabetes, Diabetologia, 43, 
703-708. 
 
Gibson C., Rubinstein A., Ginsberg H., Greten H., Norum R., and Kayden H 
(1985), ApoE-containing lipoproteins in low or high density lipoprotein deficiency, 
Arteriosclerosis, 5, 371–380. 
 
Ginsberg H (2002), New perspectives on atherogenesis role of abnormal 
triglyceride-rich lipoprotein metabolism, The Journal of American Heart 
Association, 106, 2137-2142. 
 
Ginsberg H., Zhang Y and Hernandez-Ono A (2005), Regulation of plasma 
triglycerides in insulin resistance and diabetes, Archives of Medical Research, 36, 
232-240. 
 
Ginsberg H and Brown W (2011), Apolipoprotein CIII : 42 years old and even 
more interesting, The Journal of American Heart Association, 31, 471-473. 
 
Ginsberg N (1996), Diabetic dyslipidemia:basis mechanisms underlying the 






Gloria-Botthini F., Antonacci E., Bottini N., Ogana A., and Borgiani P (2000), 
Rh blood groups and diabetic disorders: Is there an effect on glycosylated 
hemoglobin level?, Human Biology, 72(2), 287-294. 
 
Grundy M (1998), Statin trials and goals of cholesterolloweringtherapy, 
Circulation 97, 1436–1439. 
 
Haffner S (2006), Relationship of Metabolic Risk Factors and Development of 
Cardiovascular Disease and Diabetes, Obesity Research Journal 14, 121S-127S. 
 
Henry R (2001), Preventing cardiovascular complications of type 2 diabetes: Focus 
on lipid management, Clinical Diabetes, 19(3), 113-120. 
 
Hiukka A., Najib J., Leinonen E., Hilden H., Fruchart J and Taskinen M 
(2005), Alterations of lipids and apolipoprotein CIII in very low density lipoprotein 
subspecies in type 2 diabetes, Diabetologia, 48, 1207-1215. 
 
Hiukka A., Ståhlman M., Pettersson C., Levin M., Adiels M., Teneberg S., 
Leinonen E., Hulte L., and Wiklund O (2009), ApoCIII-Enriched LDL in Type 2 
Diabetes Displays Altered lipid composition, increased susceptibility for 
sphingomyelinase, and increased binding to biglycan, Diabetes, 58, 2018-2026. 
 
Hobbs F (2004), Cardiovascular disease: different strategies for primary and 
secondary prevention?, Clinical Chemistry, 51(2), 360-367. 
 
Hoek M., Herpt T., Dehghan A., Hofman A., Lieverse A., van C., Witteman J 
and Sijbrands E (2011), Association of an APOC3 promoter variant with type 2 
diabetes risk and need for insulin treatment in lean persons, Diabetologia, 54, 1360–
1367. 
 
Husseini A ., Abu-Rmeileh N., Mikki N., Ramahi T., Ghosh H., Barghuthi N., 
Khalili M., Bjertness E., Holmboe-Ottesen G and Jervell J (2009), Health in the 




cancer in the occupied Palestinian territory, Lancet Global health network, 373, 
1041-1049. 
 
Irshad M., and Dubey R (2005), Apolipoprotein and their role in different clinical 
condition: An overview, Indian Journal of Biochemistry & Biophysics, 42, 73-80. 
 
Jenni B., Stephanie G., Katherine B., Michelle H., and Robert S (2004), Clinical 
characteristics of children diagnosed with type 1 diabetes through intensive 
screening and follow-up, Diabetes Care, 27, 1399–1404. 
 
Jennifer M (1998), Diagnosis and classification of diabetes mellitus: New criteria, 
American Family physician, 58(6), 1355-1362. 
 
 
Jere S., Martin J., Hans L and Nassrin (2001), Structure of apolipoprotein B-100 
in low density lipoproteins, Journal of Lipid Research, 42, 1346-1367. 
 
Jong M., Hofker M., and Havekes L (1999), Role of apoCs in lipoprotein 
metabolism functional differences between ApoC1, ApoC2, and ApoC3, 
Arterioscler Thromb Vasc Biol, 19(472-484). 
 
Jong M., Rensen P., Dahlmans V., Boom H., Berkel T., and Havekes L (2001), 
Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein 
lipase in wild-type and apoE knockout mice, Journal of Lipid Research, 42, 1578-
1585. 
 
Kahn S., Hull R., and Utzschneider K (2006), Mechanisms linking obesity to 
insulin resistance and type 2 diabetes, Nature, 444, 840-846. 
 
Karthik B., Girish V., Sally M., and Azfar Z (2012), Increased atherothrombotic 
burden in patients with diabetes mellitus and acute coronary syndrome: A review of 
antiplatelet therapy, Cardiology Research and Practice, 1-18. 
 
Kawakami A and Yoshida M (2008), Apolipoprotein C III links dyslipidemia with 





Kawakami A., Aikawa M., Alcaide P., Luscinskas F., Libby P, and Sacks F 
(2006), Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 
in vascular endothelial cells and increases adhesion of monocytic cells, Circulation, 
114, 681-687. 
 
Kawakami A., Osaka M., Tani M., Azuma., Sacks F., Shimokado K and 
Yoshida M (2008), Apolipoprotein CIII links hyperlipidemia with vascular 
endothelial cell dysfunction, Circulation, 118, 731-742. 
 
 
Kawakami A., Osaka M., Uematsu S., Akira S., Shimokado K., Sacks F., and 
Yoshida M (2010), Apolipoprotein CIII induces monocyte chemoattractant protein-
1 and interleukin 6 expression via Toll-like receptor 2 pathway in mouse adipocytes, 
Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 2242 – 2248.  
 
Koren E., Corder C., and Mueller G (1996), Triglyceride enriched lipoprotein 
particles correlate with the severity of coronary artery disease, Atherosclerosis, 122, 
105–115. 
 
Koskinen P., Manttari M., Manninen V., Huttunen J., Heinonen P., and F  M 
(1992), Coronary heart disease incidence in the Helsinki Heart Study, Diabetes 
Care, 15, 820-825. 
 
Laakso M (1999), Perspectives in diabetes hyperglycemia and cardiovascular 
disease in type 2 diabetes, Diabetes 48, 937-942. 
 
Lee S., Campos H., Moye L., and Sacks F (2003), LDL Containing 
Apolipoprotein CIII Is an Independent Risk Factor for Coronary Events in Diabetic 
Patients, Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 853-858. 
 
Luc G., Fievet C., Arveiler D., Evans A., Bard J., Cambien F., Fruchart J., and 
Ducimetier P (1996), Apolipoproteins C-Ill and E in apoB- and non-apoB-
containing lipoproteins in two populations at contrasting risk for myocardial 





Lusis A (2000), Atherosclerosis, Nature, 14(407 ), 233–241. 
 
Mahley R., Innerarity T., Rall J., and Weisgraber K (1984), Plasma lipoproteins: 
Apolipoprotein structure and function, Journal of Lipid Research, 25(12), 1277-
1294. 
 
Mahley W., and Ji S (1999), Remnant lipoprotein metabolism: key pathways 
involving cell-surface heparan sulfate proteoglycans and apolipoprotein E, Journal 
of lipid research, 40(1), 1-16. 
 
Malati T., and Mahesh M (2009 ), Reference intervals for serum total cholesterol, 
HDL-cholesterol, LDL-cholesterol, triglyceride, Lp (a), apolipoprotein  A-I, A-II, B, 
C-II, C-III, and E in healthy south Indians from Andhra Pradesh, Indian Journal of 
Clinical Biochemistry, 24(4), 343-355. 
 
Mann J., Troussard A., and Yen T (1997), Inhibitory effects of specific 
apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the 
lipolysis-stimulated receptor, The Journal of Biological Chemistry, 272, 31348–
31354. 
 
Mannem S., Praveen K., and Gupta V (2009), Elevated CK-MB without 
myocardiacl infarction, Scintific Medicine, 1(2). 
 
Marcous C., Tremblay M., Fredenrich A., Davignon J., and Cohn J (2001), 
Lipoprotein Distribution of Apo C-III and Its Relationship to the presence in Plasma 
of Triglyceride-Rich Remnant Lipoproteins, Metabolism, 50(1), 112-119. 
 
Mead R., Irvine A., and Ramji P (2002), Lipoprotein lipase: structure, function, 
regulation, and role in disease, Journal of Molecular Medicine 80(12), 753-769. 
 
Mendivil C., Rimm E., Furtado J., Chiuve S., and Sacks F (2011), Low-Density 
Lipoproteins Containing Apolipoprotein C-III and the Risk of Coronary Heart 





Michael F (2007), Classification of diabetes: Not all hyperglycemia is the Same, 
Clinical Diabetes, 25(2), 74-76. 
 
Ministry of Health (MOH), 2012. Health annual report Palestine2011,P 40. 
 
Ministry of Health (MOH), (2011). Health annual report Palestine 2009 Gaza 
Strip, 43. 
 
Mooradian A (2009), Dyslipidemia in type 2 diabetes mellitus, Endocrinology & 
Metabolism Journal, 5(3), 150-159. 
 
Muacevic-Katanec D., and Reiner z (2011), Diabetic Dyslipidemia or 'Diabetes 
Lipidus'?, Cardiovascular Therapy, 9(3), 341-348. 
 
Nakou E., Filippatos T., Agouridis A., Kostara C., Bairaktari E., and Elisaf M 
(2010), The Effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein 
metabolism in obese hypercholesterolemic patients, Lipids, 45, 445–450. 
 
Nishida I., Nakanishi T., Yen A., Arai H., Yen T and Nishida T (1986), Nature 
of the enhancement of lecithin-cholesterol acyltransferase reaction by various 
apolipoproteins, Journal Biologyical Chemistry, 261, 12028–12035. 
 
Noma A., Hata Y and Gto Y (1991), Quantitation of serum apolipoprotein A-I,A-
II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference 
values, and age- and sex-related difference, Clinica Chimica Acta, 199, 147-157. 
 
Olivieri O., MartinelliI N., Girelli D., Pizzolo F., Friso S., Beltrame F., Lotto V., 
Annarumma L., and Corrocher R (2010), Apolipoprotein C-III predicts 
cardiovascular mortality in severe coronary artery disease and is associated with an 
enhanced plasma thrombin generation, Thrombosis and Haemostasis, 8, 463–471. 
 
Onat A., Hergenc G and Sansoy V (2003), Apolipoprotein C-III, a strong 
discriminant of coronary risk in men and a determinant of the metabolic syndrome 





Ooi E., Barrett P., Chan D and Watts G (2008), Apolipoprotein C-III: 
understanding an emerging cardiovascular risk factor, Clinical Science, 114, 611-
624. 
 
Packard C (2003), Triacylglycerol-rich lipoproteins and the generation of small, 
dense low-density lipoprotein, Biochemical Society Transactions, 31(5), 1066-1069. 
 
Pavlic M., Valéro R., Duez H., Xiao C., Szeto L., Patterson B., and Lewis G 
(2008), Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is 
stimulated plasma free fatty acids in humans, Arterioscler Thromb Vasc Biol, 28, 
1660-1665. 
 
Peppes V., Rammos G., Manios E., Koroboki E., Rokas S and Zakopoulos N 
(2008), Correlation between myocardial enzyme serum levels and markers of infl 
ammation with severity of coronary artery disease and Gensini score: A hospital-
based, prospective study in Greek patients, Clinical Interventions in Aging, 3(4), 
699–710. 
 
Petersen K., Dufour S., Hariri A., Nelson-Williams.C., Foo J., Zhang X., 
Dziura J., Lifton R and Shulman G (2010), Apolipoprotein C3 Gene Variants 




Poirier P., Giles T., Bray G., Hong Y., Stern J., Pi-Sunyer X and Eckel R 
(2006), Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect 
of weight loss an update of the 1997 American heart association scientific statement 
on obesity and heart disease from the obesity committee of the council on nutrition, 
Physical Activity, and Metabolism, American Heart Association, 113, 898-918. 
 
Pollin T, et al. (2008), A Null mutation in human APOC3 confers a favorable 






Rader D (2007), Effect of insulin resistance, dyslipidemia, and intra-abdominal 
adiposity on the development of cardiovascular disease and diabetes mellitus, The 
American Journal of Medicine, 120(3A), S12-S18. 
 
Rahman S and Zia I (2004), Prevalence of microvascular complications among 
diabetic patients, Pakistan Journal of Medical Research, 43(4). 
 
Ramella A., Rimoldi J., Prieto D., Schinella R., Sanchez A., Jaureguiberry S., 
Vela E., Ferreira T and Tricerri (2011), Human apolipoprotein A-I derived 
amyloid: Its association with atherosclerosis, PloS ONE, 6(7), e22532. 
 
Ramos H and T  Isip-Tan I (2010), Screening for diabetes mellitus among 
asymptomatic overseas filipino workers, Philippine Journal of Internal Medicine, 
48(3), 29-33. 
 
Raspe E, Duez H., Mansen A., fontaine C., fievet C., Fruchart J., Vennstrom B 
and Staels B (2002), Identification of Rev-erb as a physiological repressor of apoC-
III gene transcription, Journal of Lipid Research, 43, 2172-2179. 
 
Rlfal N and Silverman L (1986), Immunoturbidimetric techniques for quantifying 
apolipoproteins CII and CIII, Clinical Chemistry, 32(10), 1969-1972. 
 
Ross R (1999), Atherosclerosis: An inflammatory disease, The New England 
Journal of Medicine, 340, 115–126. 
 
Sacks F, Zheng C and Cohn J (2011), Complexities of plasma apolipoprotein C-III 
metabolism, Journal of Lipid Research, 52, 1067-1070. 
 
Sakurabayashi I., Satio Y., Kita T., Matsuzwa Y and Goto Y (2001), Reference 
intervals for serum apolpoprotein A-I, A-II, B. C-II, C-III and E in health Japanese 
determined with a commercial immunoturbidimetric assay and effects of sex, 
smoking, drinking, and age Lp(a) level, Clinica Chimica Acta, 312, 87-95. 
 
Scheffer P., Teerlink T., Dekker J., Bos G., Nijpels G., Diamant M., Kostense 




concentration independently predicts cardiovascular mortality: The Hoorn Study, 
Clinical chemistry, 54(8), 1325-1330. 
 
Shin J., Blanche J., Rawlings S., Fernstrom S and Krauss M (2007), Increased 
plasma concentrations of lipoprotein(a) during a low-fat, high-carbohydrate diet are 
associated with increased plasma concentrations of apolipoprotein C-III bound to 
apolipoprotein B-containing lipoproteins, The American Journal of Clinical 
Nutrition, 85, 1527–1532. 
 
Sol M., Sundsten T and Bergsten P (2009), Role of MAPK in apolipoprotein CIII- 
induced apoptosis in INS-1E cells, Lipids in Health and Disease, 8(3). 
Sorci-Thomas G and Thomas J (2002), The effects of altered apolipoprotein A-I 
structure on plasma HDL concentration, Trends in Cardiovascular Medicine, 
12(3),121-128. 
 
Stamler J., Vaccaro O and Wentworth D (1993), Diabetes, other risk factors, and 
12-yr cardiovascular mortality for men screened in the Multiple Risk Factor 
Intervention Trial, Diabetes Care, 16, 434–444. 
 
Sundaram M., Zhong S., Khalil M., Links P., Zhao Y., Iqbal J., Hussain M., 
Parks R., Wang Y and Yao Y (2010), Expression of apolipoprotein C-III in McA-
RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions, 
Journal of Lipid Research, 51, 150–161. 
 
Swahn E., Schenck H and Olsson G (1998), Omega-3 ethyl ester concentrate 
decreases total apolipoprotein CIII and increases antithrombin III in postmyocardial 
infarction patients, Clinical Drug Investigation, 15, 473-482. 
 
Tai Y., Chuang M., Chen J and Lin J (1991), Link between hypertension and 






Tenerz A., lonnberg C., Berne C., Nilsson G and Leppert J (2001), Myocardial 
infarction and prevalence of diabetes mellitus Is increased casual blood glucose at 
admission a reliable criterion for the diagnosis of diabetes?, European Heart 
Journal, 22, 1102-1110. 
 
Thomas A., Buchanan X and Anny X (2005), Gestational diabetes mellitus, The 
Journal of Clinical Investigation, 115(3), 485-491. 
 
Tracy S., Ann B and Mark F (2005), Gestational Diabetes Mellitus, Clinical 
Diabetes, 23(1), 17-23. 
 
Turner C., Millns H., Neil H., Stratton I., Manley S., Matthews D and Holman 
R (1998), Risk factors for coronary artery disease in noninsulin dependent diabetes 
mellitus: United Kingdom prospective diabetes study (UKPDS: 23), British Medical 
Journal, 316, 823–828. 
 
Vijan S and Hayward A (2004), Pharmacologic lipid-lowering therapy in type 2 
diabetes mellitus, Annals of Internal Medicine, 140(8), 650-658. 
 
Weverling-Rijnsburger E., Jonkers M., Exel E., Gussekloo J and Westendorp J 
(2003), High-density vs low-density lipoprotein cholesterol as the risk factor for 
coronary artery disease and stroke in old age., Archives of Internal Medicine, 163, 
1549–1554. 
 
World Health oragnization (WHO), (2008).Cardivascular diseases. Available on:  
http://www.who.int/cardiovascular_diseases/en/ (Accessed on 10 may 2013) 
 




http://www.who.int/mediacentre/factsheets/fs312/en/index.html  (accessed 
on 13 Ianuary). 
 
World Health oragnization (WHO), (2012).10 facts on obesity, edited. Available 
on:  
http://www.who.int/features/factfiles/obesity/facts/en/index.html (accessed 





Wild S., Roglic G., Green A., Sicree R and King H (2004), Global prevalence of 
diabetes: estimates for the year 2000 and projections for 2030, Diabetes Care, 27(5), 
1047–1053. 
 
Windler E., Chaos Y and Havela R (1980), Regulation of the Hepatic Uptake of 
Triglyceride-rich Lipoproteins in the Rat, The Journal of Biological Chemistry, 
255(17), 8303-8307. 
 
Yu J., Huang J., Liang Y., Qin B., He S., Xiao J., Wang H and Zhong R (2011), 
Lack of association between apolipoprotein C3 gene polymorphisms and risk of 
coronary heart disease in a Han population in East China, Lipids in Health and 
Disease, 1-6. 
 
Zheng C., KhooC., Ikewaki K and Sacks F (2007), Rapid turnover of 
apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the 






















































Annex  4 
Questionnaire استبيان 
 
 ٍبجسزٞش رحبىٞو ؽجٞخ ثبىجبٍؼخ اإلسالٍٞخ (  خ)ؽبىجفزيال شعباٌ عىض  أّب اىجبحضخ: 
  ُ...أسج٘ اىَسبػذح فٜ إرَبً ٕزٓ اىذساسخ ٗاىزٜ ٕٜ ثؼْ٘ا
اىسنشٛ ٍِ ٍشػٜ اىقيت ٗ األٗػٞخ اىذٍ٘ٝخ اىزِٝ ىذٌٖٝ ٍشع  ػْذ Apolipoprotein C-III ٍسز٘ٛ)رقٌٞ  
 (فٜ قطبع غضح اىْ٘ع اىضبّٜ
ل ىْب ثؼْٞخ دً إلجشاء ثؼغ اىفح٘طبد ٍِ أجو ػَو ٕزا اىجحش , ٗىنٌ ٗرىل ٍِ خاله رؼجئخ ٕزا االسزجٞبُ ٗرجشػ 
 جضٝو اىشنش, ٍغ رَْٞبرْب ىنٌ ثبىظحخ ٗاىؼبفٞخ..
 االسٌ ...........................................)اخزٞبسٛ(                     اىًٞ٘.............اىزبسٝخ...../......./.......
 ..........................                                    اىَذْٝخ..........................اىؼْ٘اُ..............
 ريٞفُ٘ /ج٘اه................................ )اخزٞبسٛ(                      اى٘ظٞفخ:.................................
 61أمضش ٍِ ⎕ 40-50  ⎕ 51-60  ⎕اىؼَش 
 ............   BMI............. اى٘صُ.................          اىط٘ه 
 شٖبدح جبٍؼٞخ     ⎕صبّ٘ٝخ      ⎕اثزذائٞخ     ⎕                                           :دساسٞخ أػيٚ شٖبدح (1
 ال ⎕ّؼٌ   ⎕ٕو أّذ ٍذخِ؟                                                  (5
 ال  ⎕ّؼٌ  ⎕ٕو رَبسط اىشٝبػخ ثبّزظبً؟                                 (7
  انتاريخ انطبي نهًزيض
 :شخض اىَشعٍْز ٍزٚ  (4
⎕  ٍِ سْ٘اد5 أمضش 
⎕ 5-10 سْ٘اد 
⎕  ٍِ سْ٘اد 10أمضش  
ال         ,, إرا مبّذ اإلجبثخ ّؼٌ  ٝشجٚ  ⎕ّؼٌ    ⎕                هم تعاَي يٍ يشاكم صحيت أو أيزاض ؟؟ (2




⎕           ًاسرفبع ػغؾ اىذ⎕  اىذُٕ٘ اسرفبع ⎕     ٍشع فٜ  اىشئخ⎕ ٛ٘فشو مي 
⎕   أٍشاع اىقيت 
 ٕو رؼزَذ فٜ رْظٌٞ ّسجخ اىسنشٛ فٜ اىذً ػيٜ:  (6
⎕  .اىحَٞخ اىغزائٞخ فقؾ 
⎕ األقشاص 
⎕.ِٞاألّس٘ى 
 ال  ⎕ّؼٌ    ⎕ٕو رزْبٗه أدٗٝٔ خبفؼٔ ىَسز٘ٛ اىذُٕ٘ فٜ اىذً ؟  (3




















Annex  5 
Questionnaire 
 
I am a researcher: Ferial Shaban Awad 
(Master student at the Islamic University Medical Technology) 
Please help me  in completing this study and which is entitled :( Assessment of 
Apolipoprotein C- III as A predictor of Cardiovascular Diseases among Type 2 
Diabetic Men in Gaza Strip) 
Through the mobilization of this questionnaire and your donation to us samples of blood 
to conduct some tests in order to do this research, 
 Thank you very much, wishes to you with health and wellness. 
   Name ………………………. (Optional)                      Date     /    /  
   Region………...                                                         Address:………  
   Tele No:……………….                                              Job:…………….. 
   Age………. 
   Height………..(cm)       Weight…………(kg) 
   BMI………… 
1)The highest academic degree 
Primary           Preparatory            Secondary          University   
2) Are you smoker?   Yes              No   
3) Do you exercise regularly?  Yes              No   
 Patient's medical history 
4) Since when suffering from diabetes?  
        Not suffering from diabetes 




        More than five years.           
5) Do you suffer from health problems or diseases?? ⎕ Yes ⎕ No, If yes, please 
indicate below to the type of the disease situation? 
⎕ Hypertension          ⎕  hyperlipidemia             ⎕ Lung disease                        
⎕ Kidney Diseases              ⎕Heart disease 
6) Do you  regulate blood glucose based on: 
⎕Diet Only        ⎕ oral agent    ⎕ insulin only   
7) Are you taking drugs decreases the level of fat in the blood?  ⎕ Yes ⎕ No 






     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
